

*PBS
Expenditure
and
Prescriptions
Report
1 July 2021
to
30 June 2022*



Australian Government

Department of Health
and Aged Care

***PBS Analytics and Strategic Insight Section
Pricing and PBS Policy Branch
Technology Assessment and Access Division***

This publication and previous editions can be accessed via the internet:
<http://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries or feedback to:

Surface mail: Director
PBS Analytics and Strategic Insight Section
Pricing and PBS Policy Branch, MDP 900
Department of Health and Aged Care
GPO Box 9848 Canberra ACT 2601

E-mail: pbsstats@health.gov.au

Important Information

Unless otherwise indicated this publication has been produced using data provided to the Department of Health and Aged Care by Services Australia. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by Services Australia. They refer only to paid services processed for prescriptions submitted and claimed via the PBS Online claiming system by approved suppliers. Claims of manually processed PBS programs are excluded.

PBS Expenditure includes the following patient categories:

- General - Non-Safety Net (Ordinary)
- General - Safety Net
- Concessional - Non-Safety Net (Ordinary)
- Concessional - Safety Net
- Doctor's Bag

The financial information in this publication is presented on a cash (expenditure) basis, except where indicated otherwise.

The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:

- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card

There are two safety net thresholds – one for General patients and the other for Concessional patients.

From 1 January 2022, the general patient safety net threshold was **\$1,542.10**. When patients and/or their families reached this amount, they could apply for a Safety Net Card and pay only **\$6.80** per prescription for the rest of the calendar year. The concessional safety net threshold was **\$326.40**. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.

The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.

From 2016-17 this publication is based on the date that a prescription medicine was supplied to a patient. Previous publications were based on the date that a claim was processed (and the payment finalised) by Services Australia. The historical data from 1948-49 to 2015-16 on pages 28 to 33 remains by date of processing.

Caution should be exercised in referring to the breakdown by patient category in Table 21(a) on pages 28 to 29 and Table 21(b) on pages 30 to 33, because of a past problem in supply data whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem was fixed from 2008-09 onwards, but the

2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

While Section 100 data has been included in the majority of tables in this report, this data does not include supplies to Remote Area Aboriginal Health Services with the exception of Tables 1(a) and 1(b) on page 1.

Expenditure on nusinersen and onasemnogene abeparvovec was adjusted to include manual payments that were not processed through the PBS Online system.

The Department of Health and Aged Care has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

Summary of the Pharmaceutical Benefits Scheme 2021-22

Total Pharmaceutical Benefits Scheme (PBS) Government expense for the supply of medicines under Section 85 and Section 100 on an accrual accounting basis for the 2021-22 financial year was **\$14.7 billion** (excluding revenue), compared with **\$13.8 billion** for the previous year. This is an increase of **6.7%**.

The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by financial year (based on date of supply); however, a few tables refer to Section 85 only and some tables report pharmacy program expenditure.

Total 2021-22 PBS subsidised prescription volume increased by **0.7%** to a total of **215.0 million**, compared to **213.6 million** for the 2020-21 financial year.

In 2021-22, PBS Government expenditure on a cash accounting basis for the supply of medicines under Section 85 and Section 100 was **\$14.5 billion** (excluding rebates) which is **90.1%** of the total cost of PBS prescriptions. The remainder was patient contributions, which amounted to **\$1.6 billion**.

The majority of Government expenditure in 2021-22 on PBS Section 85 and Section 100 prescriptions was directed towards concessional cardholders (**\$9.3 billion, 64.4% of the total**), compared to concessional cardholders expenditure for 2020-21 (**\$9.0 billion, 66.3%** of the total).

The average dispensed price (Patient payment plus Government benefit) per prescription of PBS subsidised medicines increased to **\$74.67** in 2021-22, compared to **\$70.65** in 2020-21.

There were **925** different medicines in **5,178** brands listed on the PBS as at 30 June 2022.

List of tables

Table	Description	Page
Table 1(a)	PBS Expense on an Accrual Accounting Basis, 2020-21 and 2021-22	1
Table 1(b)	PBS Section 100 Programs on an Accrual Accounting Basis, 2020-21 and 2021-22	1
Table 2(a)	PBS Prescriptions, 2020-21 and 2021-22	2
Table 2(b)	PBS Government Cost, 2020-21 and 2021-22	2
Table 2(c)	RPBS and PBS Subsidised Prescriptions for DVA patients, 2020-21 and 2021-22	2
Table 2(d)	RPBS and PBS Government Cost for DVA patients, 2020-21 and 2021-22	2
Table 3(a)	PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2021-22	3
Table 3(b)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2021-22	3
Table 3(c)	PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2020-21 and 2021-22	3
Table 4	PBS Subsidised Prescriptions by Pharmacy State, 2021-22	4
Table 5(a)	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2021-22	5
Table 5(b)	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2021-22	6
Table 5(c)	Top 25 PBS Cancer Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2021-22	7
Table 5(d)	Top 25 PBS Biologic Products and Medicines Sorted by Highest Government Cost, 2021-22	7
Table 6	Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2021-22	8
Table 7	Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2021-22	9
Table 8	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2020-21 and 2021-22	10
Table 9(a)	Top 35 Drugs Sorted by Highest Change to Government Cost, 2020-21 and 2021-22	11
Table 9(b)	Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2020-21 and 2021-22	12
Table 10(a)	PBS Section 85 Prescription Volume, 2018-19 to 2021-22	13
Table 10(b)	PBS Section 85 expenditure, 2018-19 to 2021-22	13
Table 11	PBS Prescriptions and Government Cost by Formulary, 2021-22	14
Table 12(a)	Top 20 Responsible Persons by Total Cost, 2021-22	15
Table 12(b)	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2021-22	16
Table 12(c)	Top 20 Responsible Persons by Total PBS Prescriptions, 2021-22	17

Table 13	Number of PBS Approved Suppliers, 30 June 2022	18
Table 14	PBS Brand Premiums, 2021-22	18
Table 15(a)	PBS/RPBS prescriptions dispensed by Community Pharmacies, 2021-22	19
Table 15(b)	PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2021-22	19
Table 16(a)	PBS/RPBS Medicines Supplied under Continued Dispensing by Dispensing Pharmacy State, 2021-22	20
Table 16(b)	PBS/RPBS Continued Dispensing Medicines Government Cost by Dispensing Pharmacy State, 2021-22	20
Table 16(c)	PBS/RPBS Medicines Supplied under Continued Dispensing (Emergency Measures) by ATC Level 1 and Dispensing Pharmacy State, 2021-22	21
Table 16(d)	PBS/RPBS Continued Dispensing (Emergency Measures) Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2021-22	21
Supplement 1	Community Pharmacy Agreement (CPA) Expenses	
Table 17	Remuneration for Community Pharmacies and Friendly Societies for PBS subsidised prescriptions, 2020-21 to 2021-22	22
Table 18	CPA Professional Pharmacy Programs Expenditure, 2021-22	23
Table 19	Actual Costs of Major Components of CPA, 2021-22	24
Table 20	Community Services Obligation (CSO) Expenditure, 2021-22	24
Supplement 2	PBS Information Line Report, 2021-22	25
Supplement 3	National Diabetes Services Scheme (NDSS)	26
Supplement 4	Historical PBS Prescriptions and Expenditure	
Table 21(a)	Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2021-22)	28
Table 21(b)	Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2021-22)	30

Table 1(a): PBS Expense on an Accrual Accounting Basis, 2020-21 and 2021-22

Category	2020-21	Percentage of Total	2021-22	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$6,884,024,680	50.1%	\$7,214,557,536	49.2%	\$330,532,855	4.8%
Section 85 - General	\$2,405,632,262	17.5%	\$2,877,955,808	19.6%	\$472,323,546	19.6%
Doctor's Bag	\$16,685,943	0.1%	\$15,940,398	0.1%	-\$745,545	-4.5%
Section 100*	\$4,429,279,015	32.2%	\$4,547,719,795	31.0%	\$118,440,780	2.7%
Safety Net Cards	\$15,034,724	0.1%	\$14,478,285	0.1%	-\$556,440	-3.7%
Total	\$13,750,656,624	100.0%	\$14,670,651,822	100.0%	\$919,995,197	6.7%
Total Including Revenue	\$10,270,867,025		\$10,924,747,250		\$653,880,225	6.4%

*Individual S100 programs are shown in Table 1(b).

Table 1(b): PBS Section 100 Programs on an Accrual Accounting Basis, 2020-21 and 2021-22

Category	2020-21	Percentage of Total	2021-22	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs	\$2,102,049,020	47.5%	\$2,156,466,697	47.4%	\$54,417,677	2.6%
Chemotherapy (EFC & Chemotherapy-related)	\$1,895,181,306	42.8%	\$1,906,534,154	41.9%	\$11,352,847	0.6%
In Vitro Fertilisation	\$157,416,057	3.6%	\$151,496,719	3.3%	-\$5,919,339	-3.8%
Opiate Dependence Treatment Program*	\$90,681,291	2.0%	\$108,372,517	2.4%	\$17,691,226	19.5%
Aboriginal Health Services (GST exclusive)	\$50,012,059	1.1%	\$54,529,630	1.2%	\$4,517,571	9.0%
Botulinum Toxin Program (incl. Dysport)	\$68,154,459	1.5%	\$67,378,254	1.5%	-\$776,205	-1.1%
Growth Hormone	\$34,352,692	0.8%	\$35,601,253	0.8%	\$1,248,561	3.6%
Paraplegic and Quadriplegic Program	\$227,038	0.0%	\$172,655	0.0%	-\$54,383	-24.0%
Medication Program for Homeless People	\$138,601	0.0%	\$120,863	0.0%	-\$17,738	-12.8%
Closing the Gap (CTG) PBS Co-payment Program**	\$31,066,492	0.7%	\$67,047,055	1.5%	\$35,980,563	115.8%
Total	\$4,429,279,015	100.0%	\$4,547,719,795	100.0%	\$118,440,780	2.7%

Note:

Expense figures refer to payments made through the Services Australia and directly from the Department of Health and Aged Care Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on www.pbs.gov.au.

* There has been an increase in ODTP expenditure since the listing of long acting injectable buprenorphine injection formulations in 2019. 2021-22 shows a continuation in increase although smaller than seen in 2020-21.

** Figures include expenditure from 1 January 2021 onwards. Prior to this date funding for the CTG PBS Co-payment Program was provided under the Indigenous Australians' Health Programme, Bill 1 Appropriation

Table 2(a): PBS Prescriptions, 2020-21 and 2021-22

Section 85 and S100, including Drs Bag and under co-payment prescriptions

Patient Category	2020-21		2021-22		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	144,112,808	67.5%	143,684,343	66.8%	-428,465	-0.3%
Concessional Safety Net	50,746,705	23.8%	50,551,722	23.5%	-194,983	-0.4%
Total Concessional	194,859,513	91.2%	194,236,065	90.3%	-623,448	-0.3%
General Non-Safety Net	15,552,857	7.3%	17,550,757	8.2%	1,997,900	12.8%
General Safety Net	2,813,837	1.3%	2,875,409	1.3%	61,572	2.2%
Total General	18,366,694	8.6%	20,426,166	9.5%	2,059,472	11.2%
Doctors Bag	360,465	0.2%	355,487	0.2%	-4,978	-1.4%
Total (Over Co-payment)	213,586,672	100.0%	215,017,718	100.0%	1,431,046	0.7%
Under Co-payment	93,594,137		100,790,420		7,196,283	7.7%
Total (Over and Under Co-payment)	307,180,809		315,808,138		8,627,329	2.8%

Table 2(b): PBS Government Cost, 2020-21 and 2021-22

Section 85 and S100, including Drs Bag and excluding under co-payment prescriptions

Patient Category	2020-21		2021-22		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$7,010,810,041	51.7%	\$7,266,742,606	50.3%	\$255,932,565	3.7%
Concessional Safety Net	\$1,985,353,714	14.6%	\$2,034,655,830	14.1%	\$49,302,116	2.5%
Total Concessional	\$8,996,163,756	66.3%	\$9,301,398,436	64.4%	\$305,234,681	3.4%
General Non-Safety Net	\$4,414,820,818	32.5%	\$4,978,558,319	34.5%	\$563,737,502	12.8%
General Safety Net	\$147,500,170	1.1%	\$156,382,164	1.1%	\$8,881,994	6.0%
Total General	\$4,562,320,987	33.6%	\$5,134,940,483	35.5%	\$572,619,496	12.6%
Doctors Bag	\$14,971,503	0.1%	\$14,228,777	0.1%	-\$742,725	-5.0%
Total (Over Co-payment)	\$13,573,456,246	100.0%	\$14,450,567,697	100.0%	\$877,111,451	6.5%

Table 2(c): RPBS and PBS Subsidised Prescriptions for DVA patients, 2020-21 and 2021-22

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2020-21		2021-22		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	5,106,120	66.7%	4,890,887	67.3%	-215,233	-4.2%
Repatriation Safety Net	2,544,802	33.3%	2,372,281	32.7%	-172,521	-6.8%
Total Repatriation	7,650,922	100.0%	7,263,168	100%	-387,754	-5.1%

Table 2(d): RPBS and PBS Government Cost for DVA patients, 2020-21 and 2021-22

PBS Section 85 and S100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2020-21		2021-22		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$236,199,145	72.0%	\$246,030,487	73.1%	\$9,831,343	4.2%
Repatriation Safety Net	\$91,964,706	28.0%	\$90,390,115	26.9%	-\$1,574,591	-1.7%
Total Repatriation	\$328,163,851	100.0%	\$336,420,603	100.0%	\$8,256,751	2.5%

Table 3(a): PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2021-22
Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2021-22	Concessional Non-Safety Net	142,223,258	\$5,179,039,991	\$920,942,920	\$6,099,982,911	\$42.89
	Concessional Safety Net	50,372,858	\$1,843,118,166	\$0	\$1,843,118,166	\$36.59
	Total Concessional	192,596,116	\$7,022,158,157	\$920,942,920	\$7,943,101,076	\$41.24
	General Non-Safety Net	15,874,460	\$2,707,518,000	\$595,270,318	\$3,302,788,317	\$208.06
	General Safety Net	2,847,994	\$128,887,707	\$18,163,632	\$147,051,339	\$51.63
	Total General	18,722,454	\$2,836,405,707	\$613,433,949	\$3,449,839,656	\$184.26
	Total (excluding Drs Bag)	211,318,570	\$9,858,563,864	\$1,534,376,869	\$11,392,940,733	\$53.91
	Doctors Bag	355,487	\$14,228,777	\$0	\$14,228,777	\$40.03
Total (including Drs Bag)	211,674,057	\$9,872,792,641	\$1,534,376,869	\$11,407,169,510	\$53.89	

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(b): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2021-22
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2021-22	Concessional Non-Safety Net	143,684,343	\$7,266,742,606	\$927,830,093	\$8,194,572,699	\$57.03
	Concessional Safety Net	50,551,722	\$2,034,655,830	\$0	\$2,034,655,830	\$40.25
	Total Concessional	194,236,065	\$9,301,398,436	\$927,830,093	\$10,229,228,529	\$52.66
	General Non-Safety Net	17,550,757	\$4,978,558,319	\$646,447,351	\$5,625,005,670	\$320.50
	General Safety Net	2,875,409	\$156,382,164	\$18,303,184	\$174,685,348	\$60.75
	Total General	20,426,166	\$5,134,940,483	\$664,750,535	\$5,799,691,018	\$283.93
	Total (excluding Drs Bag)	214,662,231	\$14,436,338,920	\$1,592,580,628	\$16,028,919,547	\$74.67
	Doctors Bag	355,487	\$14,228,777	\$0	\$14,228,777	\$40.03
Total (including Drs Bag)	215,017,718	\$14,450,567,697	\$1,592,580,628	\$16,043,148,325	\$74.61	

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(c): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2020-21 and 2021-22
Section 85 and Section 100, excluding Drs Bag and including under co-payment prescriptions

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Ave. Price**
2020	Jul	18,348,194	7,914,602	26,262,796	\$1,161,610,868	\$126,734,208	\$1,288,345,076	\$70.22
	Aug	17,675,178	7,649,373	25,324,551	\$1,108,782,271	\$114,308,123	\$1,223,090,395	\$69.20
	Sep	18,024,217	7,445,374	25,469,591	\$1,162,818,934	\$108,376,630	\$1,271,195,564	\$70.53
	Oct	18,582,816	7,552,973	26,135,789	\$1,160,228,387	\$105,121,410	\$1,265,349,797	\$68.09
	Nov	18,360,692	7,342,431	25,703,123	\$1,158,880,294	\$98,357,102	\$1,257,237,395	\$68.47
	Dec	21,392,776	7,613,728	29,006,504	\$1,292,381,507	\$100,602,499	\$1,392,984,007	\$65.11
2021	Jan	14,988,738	7,541,346	22,530,084	\$980,643,429	\$132,824,204	\$1,113,467,633	\$74.29
	Feb	15,634,452	7,402,171	23,036,623	\$1,017,094,412	\$137,455,168	\$1,154,549,579	\$73.85
	Mar	18,219,200	8,486,234	26,705,434	\$1,201,400,625	\$158,797,370	\$1,360,197,994	\$74.66
	Apr	16,783,027	7,869,306	24,652,333	\$1,049,343,820	\$142,493,801	\$1,191,837,621	\$71.01
	May	17,473,456	8,400,419	25,873,875	\$1,114,727,555	\$143,064,567	\$1,257,792,121	\$71.98
	Jun	17,743,461	8,376,168	26,119,629	\$1,150,572,642	\$136,196,186	\$1,286,768,828	\$72.52
Total		213,226,207	93,594,125	306,820,332	\$13,558,484,743	\$1,504,331,268	\$15,062,816,011	\$70.64
2021	Jul	18,281,281	8,569,969	26,851,250	\$1,177,672,935	\$131,285,179	\$1,308,958,114	\$71.60
	Aug	18,361,327	8,480,561	26,841,888	\$1,213,285,472	\$123,266,631	\$1,336,552,103	\$72.79
	Sep	18,126,933	8,018,036	26,144,969	\$1,214,252,049	\$113,124,033	\$1,327,376,082	\$73.23
	Oct	18,173,349	7,975,312	26,148,661	\$1,188,694,019	\$107,663,169	\$1,296,357,188	\$71.33
	Nov	18,997,813	8,010,720	27,008,533	\$1,277,335,593	\$105,639,696	\$1,382,975,289	\$72.80
	Dec	21,144,777	8,176,775	29,321,552	\$1,349,824,185	\$104,834,952	\$1,454,659,138	\$68.80
2022	Jan	15,270,455	8,091,814	23,362,269	\$1,037,856,411	\$143,288,803	\$1,181,145,214	\$77.35
	Feb	15,577,116	7,767,222	23,344,338	\$1,059,826,931	\$144,551,954	\$1,204,378,885	\$77.32
	Mar	18,024,794	8,958,303	26,983,097	\$1,237,076,252	\$165,869,359	\$1,402,945,611	\$77.83
	Apr	16,748,507	8,429,408	25,177,915	\$1,129,339,116	\$150,871,015	\$1,280,210,132	\$76.44
	May	18,035,114	9,203,308	27,238,422	\$1,269,103,155	\$156,164,975	\$1,425,268,130	\$79.03
	Jun	17,920,765	9,108,976	27,029,741	\$1,282,072,802	\$146,020,861	\$1,428,093,663	\$79.69
Total		214,662,231	100,790,404	315,452,635	\$14,436,338,920	\$1,592,580,628	\$16,028,919,547	\$74.67

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 4: PBS Subsidised Prescriptions by Pharmacy State, 2021-22

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

PBS S85 subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	45,384,966	35,314,680	29,995,539	12,006,589	13,348,453	4,124,754	560,186	1,488,091	142,223,258
Concessional Safety Net	16,880,058	12,264,383	10,494,405	4,199,742	4,409,556	1,504,098	98,530	522,086	50,372,858
General Non-Safety Net	5,108,679	3,744,419	3,349,412	1,013,470	1,776,273	371,838	156,198	354,171	15,874,460
General Safety Net	978,371	685,689	519,822	187,217	326,326	58,308	9,289	82,972	2,847,994
Total	68,352,074	52,009,171	44,359,178	17,407,018	19,860,608	6,058,998	824,203	2,447,320	211,318,570
PBS (S85 + S100) subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	45,828,955	35,681,329	30,303,549	12,126,231	13,488,939	4,162,506	571,741	1,521,093	143,684,343
Concessional Safety Net	16,932,373	12,314,955	10,531,742	4,213,656	4,426,239	1,509,158	99,108	524,491	50,551,722
General Non-Safety Net	5,650,485	4,167,828	3,649,454	1,123,506	1,960,117	398,116	171,736	429,515	17,550,757
General Safety Net	984,683	695,413	525,851	188,354	329,648	58,646	9,427	83,387	2,875,409
Total	69,396,496	52,859,525	45,010,596	17,651,747	20,204,943	6,128,426	852,012	2,558,486	214,662,231
Government Cost (S85 only)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$1,673,593,638	\$1,269,132,476	\$1,080,779,820	\$430,727,588	\$493,586,735	\$154,682,986	\$19,064,073	\$57,472,675	\$5,179,039,991
Concessional Safety Net	\$610,647,467	\$449,348,158	\$380,296,136	\$154,294,878	\$166,909,738	\$57,616,284	\$3,248,596	\$20,756,909	\$1,843,118,166
General Non-Safety Net	\$871,127,403	\$716,815,207	\$497,949,465	\$184,543,700	\$291,037,660	\$67,594,380	\$17,945,944	\$60,504,241	\$2,707,518,000
General Safety Net	\$43,648,974	\$32,082,772	\$22,560,938	\$8,327,304	\$15,033,853	\$2,913,189	\$323,573	\$3,997,105	\$128,887,707
Total	\$3,199,017,481	\$2,467,378,614	\$1,981,586,359	\$777,893,470	\$966,567,985	\$282,806,839	\$40,582,187	\$142,730,930	\$9,858,563,864
Government Cost (S85 + S100)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$2,295,830,585	\$1,763,883,209	\$1,568,782,578	\$609,890,562	\$698,007,582	\$215,100,712	\$29,899,644	\$85,347,734	\$7,266,742,606
Concessional Safety Net	\$658,822,209	\$500,420,973	\$426,008,886	\$173,106,780	\$185,669,776	\$64,601,272	\$3,371,878	\$22,654,057	\$2,034,655,830
General Non-Safety Net	\$1,604,883,581	\$1,260,981,443	\$943,006,813	\$334,394,626	\$566,356,108	\$105,152,827	\$37,593,981	\$126,188,941	\$4,978,558,319
General Safety Net	\$49,881,036	\$40,658,742	\$28,408,935	\$9,980,541	\$18,950,104	\$3,494,386	\$361,960	\$4,646,461	\$156,382,164
Total	\$4,609,417,411	\$3,565,944,366	\$2,966,207,211	\$1,127,372,509	\$1,468,983,571	\$388,349,197	\$71,227,464	\$238,837,192	\$14,436,338,920
Total Cost (S85 + S100)*	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$2,589,721,282	\$2,000,314,184	\$1,761,285,573	\$688,802,859	\$784,630,484	\$241,675,120	\$32,819,150	\$95,324,046	\$8,194,572,699
Concessional Safety Net	\$658,822,209	\$500,420,973	\$426,008,886	\$173,106,780	\$185,669,776	\$64,601,272	\$3,371,878	\$22,654,057	\$2,034,655,830
General Non-Safety Net	\$1,808,648,914	\$1,426,402,513	\$1,070,188,610	\$376,270,375	\$639,130,633	\$119,005,321	\$42,262,212	\$143,097,092	\$5,625,005,670
General Safety Net	\$56,115,168	\$45,195,311	\$31,693,952	\$11,187,047	\$21,041,948	\$3,855,070	\$409,281	\$5,187,571	\$174,685,348
Total	\$5,113,307,575	\$3,972,332,980	\$3,289,177,022	\$1,249,367,061	\$1,630,472,841	\$429,136,783	\$78,862,521	\$266,262,765	\$16,028,919,547
Population Percentage	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Population**	8,095,430	6,559,941	5,265,043	1,806,599	2,762,234	569,827	249,345	453,324	25,766,605
PBS S85 Subsidised Scripts per Capita	8.44	7.93	8.43	9.64	7.19	10.63	3.31	5.40	8.20
PBS (S85 + S100) Subsidised Scripts per Capita	8.57	8.06	8.55	9.77	7.31	10.75	3.42	5.64	8.33
PBS S85 Govt Cost per Capita	\$395.16	\$376.13	\$376.37	\$430.58	\$349.92	\$496.30	\$162.76	\$314.85	\$382.61
PBS (S85 + S100) Govt Cost per Capita	\$569.39	\$543.59	\$563.38	\$624.03	\$531.81	\$681.52	\$285.66	\$526.86	\$560.27
Population Percentage	31.42%	25.46%	20.43%	7.01%	10.72%	2.21%	0.97%	1.76%	100.00%
PBS (S85 + S100) Subsidised Scripts Percentage	32.33%	24.62%	20.97%	8.22%	9.41%	2.85%	0.40%	1.19%	100.00%
PBS (S85 + S100) Govt Cost Percentage	31.93%	24.70%	20.55%	7.81%	10.18%	2.69%	0.49%	1.65%	100.00%
Total Cost Percentage	31.90%	24.78%	20.52%	7.79%	10.17%	2.68%	0.49%	1.66%	100.00%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 + S100 prescriptions).

**Population 31 December 2021, Source: ABS Publication 3101.04

Table 5(a): Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2021-22
 Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	AFLIBERCEPT	404,089	\$481,028,749	\$6,378,324	\$487,407,073	\$1,206.19
2	PEMBROLIZUMAB	50,296	\$427,011,809	\$235,725	\$427,247,534	\$8,494.66
3	NIVOLUMAB	51,323	\$395,640,907	\$261,418	\$395,902,325	\$7,713.94
4	USTEKINUMAB	42,062	\$300,245,114	\$1,285,837	\$301,530,951	\$7,168.73
5	ADALIMUMAB	304,799	\$273,394,919	\$8,718,161	\$282,113,080	\$925.57
6	APIXABAN	3,322,445	\$270,690,520	\$40,023,903	\$310,714,423	\$93.52
7	DENOSUMAB	1,008,022	\$253,150,145	\$12,133,915	\$265,284,060	\$263.17
8	LENALIDOMIDE	43,723	\$240,149,272	\$887,896	\$241,037,169	\$5,512.82
9	OCRELIZUMAB	11,169	\$194,040,084	\$377,848	\$194,417,932	\$17,406.92
10	RANIBIZUMAB	163,599	\$189,491,815	\$2,274,430	\$191,766,245	\$1,172.17
11	RIVAROXABAN	2,439,138	\$162,827,092	\$34,476,958	\$197,304,050	\$80.89
12	DUPILUMAB	92,352	\$157,758,778	\$2,882,354	\$160,641,131	\$1,739.44
13	IPILIMUMAB	7,595	\$151,785,659	\$80,146	\$151,865,805	\$19,995.50
14	GLECAPREVIR + PIBRENTASVIR	7,326	\$135,620,566	\$197,383	\$135,817,949	\$18,539.17
15	ATEZOLIZUMAB	17,779	\$132,723,584	\$105,848	\$132,829,432	\$7,471.14
16	IBRUTINIB	14,111	\$130,265,093	\$200,626	\$130,465,719	\$9,245.67
17	SOFOSBUVIR + VELPATASVIR	10,042	\$126,437,383	\$200,027	\$126,637,410	\$12,610.78
18	TEZACAFTOR + IVACAFTOR (&) IVACAFTOR	6,212	\$123,885,666	\$114,191	\$123,999,857	\$19,961.34
19	OSIMERTINIB	15,078	\$119,661,656	\$305,388	\$119,967,044	\$7,956.43
20	LUMACAFTOR + IVACAFTOR	6,517	\$116,050,867	\$82,307	\$116,133,174	\$17,820.04
21	ENZALUTAMIDE	32,235	\$113,265,152	\$388,160	\$113,653,311	\$3,525.77
22	FERRIC CARBOXYMALTOSE	432,678	\$113,205,859	\$12,000,557	\$125,206,415	\$289.38
23	ETANERCEPT	104,685	\$107,681,654	\$2,433,871	\$110,115,526	\$1,051.87
24	VEDOLIZUMAB	37,665	\$104,140,849	\$1,272,375	\$105,413,224	\$2,798.70
25	FINGOLIMOD	47,334	\$103,715,528	\$1,335,228	\$105,050,757	\$2,219.35
26	INFLIXIMAB	75,912	\$103,191,081	\$2,618,924	\$105,810,004	\$1,393.85
27	SACUBITRIL + VALSARTAN	543,501	\$102,929,230	\$7,431,297	\$110,360,527	\$203.05
28	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	57,417	\$102,196,234	\$1,727,686	\$103,923,920	\$1,809.99
29	SEMAGLUTIDE	858,460	\$96,985,456	\$17,197,649	\$114,183,105	\$133.01
30	DARATUMUMAB	12,861	\$96,395,347	\$128,911	\$96,524,258	\$7,505.19
31	ROSUVASTATIN	9,095,870	\$94,813,550	\$46,903,517	\$141,717,066	\$15.58
32	GUSELKUMAB	25,090	\$94,475,719	\$772,610	\$95,248,328	\$3,796.27
33	PALBOCICLIB	22,300	\$93,836,791	\$431,942	\$94,268,733	\$4,227.30
34	UPADACITINIB	73,379	\$91,927,542	\$1,767,626	\$93,695,167	\$1,276.87
35	DULAGLUTIDE	753,874	\$88,046,248	\$11,645,871	\$99,692,119	\$132.24
36	SECUKINUMAB	63,551	\$86,383,152	\$1,800,328	\$88,183,481	\$1,387.60
37	GOLIMUMAB	74,074	\$83,896,729	\$2,075,519	\$85,972,248	\$1,160.63
38	ESOMEPRAZOLE	5,702,279	\$81,392,899	\$27,663,756	\$109,056,654	\$19.13
39	PALIPERIDONE	234,753	\$81,299,991	\$2,453,434	\$83,753,425	\$356.77
40	ATORVASTATIN	7,971,415	\$80,681,721	\$39,722,038	\$120,403,760	\$15.10
41	DARBEPOETIN ALFA	72,836	\$78,995,201	\$1,044,225	\$80,039,426	\$1,098.90
42	CLADRIBINE	4,609	\$77,675,508	\$127,090	\$77,802,598	\$16,880.58
43	TOFACITINIB	63,116	\$77,443,540	\$1,389,850	\$78,833,390	\$1,249.02
44	FLUTICASON PROPRIONATE + SALMETEROL	2,021,562	\$77,400,384	\$38,763,723	\$116,164,106	\$57.46
45	ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR	3,481	\$74,359,141	\$59,418	\$74,418,559	\$21,378.50
46	RIBOCICLIB	16,182	\$74,117,965	\$323,217	\$74,441,182	\$4,600.25
47	TRASTUZUMAB	62,071	\$70,647,722	\$814,842	\$71,462,564	\$1,151.30
48	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	2,084,796	\$69,927,078	\$43,919,307	\$113,846,384	\$54.61
49	RUXOLITINIB	15,020	\$69,903,032	\$240,094	\$70,143,126	\$4,669.98
50	DURVALUMAB	10,570	\$68,163,524	\$39,536	\$68,203,059	\$6,452.51

* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 5(b): Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Subsidised Prescriptions, 2021-22
 Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	ROSUVASTATIN	9,095,870	\$94,813,550	\$46,903,517	\$141,717,066	\$15.58
2	ATORVASTATIN	7,971,415	\$80,681,721	\$39,722,038	\$120,403,760	\$15.10
3	PANTOPRAZOLE	6,636,707	\$64,467,338	\$31,850,784	\$96,318,121	\$14.51
4	ESOMEPRAZOLE	5,702,279	\$81,392,899	\$27,663,756	\$109,056,654	\$19.13
5	PERINDOPRIL	4,154,721	\$42,443,122	\$21,458,296	\$63,901,418	\$15.38
6	METFORMIN	3,555,331	\$41,496,824	\$16,130,368	\$57,627,192	\$16.21
7	APIXABAN	3,322,445	\$270,690,520	\$40,023,903	\$310,714,423	\$93.52
8	PREGABALIN	3,098,435	\$55,950,444	\$13,080,275	\$69,030,719	\$22.28
9	AMLODIPINE	3,075,028	\$26,332,074	\$15,290,236	\$41,622,311	\$13.54
10	SALBUTAMOL	2,722,818	\$47,360,695	\$11,465,857	\$58,826,552	\$21.61
11	IRBESARTAN	2,670,202	\$25,878,869	\$13,573,005	\$39,451,874	\$14.77
12	TELMISARTAN	2,508,183	\$25,537,125	\$13,303,023	\$38,840,148	\$15.49
13	RIVAROXABAN	2,439,138	\$162,827,092	\$34,476,958	\$197,304,050	\$80.89
14	SERTRALINE	2,412,280	\$22,760,672	\$12,755,929	\$35,516,601	\$14.72
15	CANDESARTAN	2,402,814	\$23,805,555	\$12,532,249	\$36,337,803	\$15.12
16	ESCITALOPRAM	2,373,466	\$22,726,766	\$12,739,474	\$35,466,240	\$14.94
17	MIRTAZAPINE	2,282,051	\$26,266,137	\$10,862,239	\$37,128,376	\$16.27
18	CEFALEXIN	2,172,083	\$20,568,164	\$11,420,514	\$31,988,678	\$14.73
19	RAMIPRIL	2,103,325	\$20,221,798	\$10,441,805	\$30,663,602	\$14.58
20	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	2,084,796	\$69,927,078	\$43,919,307	\$113,846,384	\$54.61
21	ATENOLOL	2,044,537	\$18,754,875	\$9,939,295	\$28,694,170	\$14.03
22	FLUTICASONE PROPIONATE + SALMETEROL	2,021,562	\$77,400,384	\$38,763,723	\$116,164,106	\$57.46
23	OXYCODONE	1,990,877	\$47,138,783	\$10,558,839	\$57,697,622	\$28.98
24	PARACETAMOL + CODEINE	1,971,330	\$35,587,249	\$10,989,533	\$46,576,781	\$23.63
25	METOPROLOL TARTRATE	1,846,006	\$17,876,565	\$8,459,492	\$26,336,056	\$14.27
26	VENLAFAXINE	1,838,819	\$22,260,216	\$9,404,650	\$31,664,866	\$17.22
27	CLOPIDOGREL	1,819,062	\$21,521,540	\$8,015,997	\$29,537,537	\$16.24
28	AMITRIPTYLINE	1,745,798	\$18,612,682	\$8,103,402	\$26,716,085	\$15.30
29	LERCANIDIPINE	1,714,888	\$17,812,723	\$8,161,715	\$25,974,439	\$15.15
30	RABEPRAZOLE	1,713,267	\$17,634,328	\$8,327,706	\$25,962,034	\$15.15
31	PARACETAMOL	1,629,451	\$24,211,906	\$6,056,746	\$30,268,652	\$18.58
32	PERINDOPRIL + AMLODIPINE	1,616,435	\$18,922,376	\$8,868,067	\$27,790,443	\$17.19
33	SIMVASTATIN	1,613,766	\$15,218,170	\$7,919,814	\$23,137,985	\$14.34
34	BISOPROLOL	1,605,556	\$25,400,105	\$7,397,633	\$32,797,738	\$20.45
35	SITAGLIPTIN + METFORMIN	1,532,676	\$59,338,226	\$25,692,141	\$85,030,367	\$55.48
36	DUTASTERIDE + TAMSULOSIN	1,503,918	\$38,489,130	\$7,148,719	\$45,637,849	\$30.35
37	FUROSEMIDE (FRUSEMIDE)	1,496,666	\$14,971,026	\$6,123,327	\$21,094,353	\$14.09
38	DIAZEPAM	1,486,929	\$12,546,963	\$7,256,588	\$19,803,551	\$13.32
39	AMOXICILLIN	1,458,467	\$13,792,779	\$8,133,804	\$21,926,583	\$15.03
40	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,391,708	\$14,767,395	\$7,185,053	\$21,952,448	\$15.77
41	GLICLAZIDE	1,355,465	\$20,128,839	\$5,675,895	\$25,804,734	\$19.04
42	OXYCODONE + NALOXONE	1,347,829	\$55,140,451	\$8,718,204	\$63,858,655	\$47.38
43	MELOXICAM	1,338,328	\$14,487,635	\$6,742,877	\$21,230,512	\$15.86
44	TIOTROPIUM	1,293,787	\$44,019,069	\$11,663,485	\$55,682,554	\$43.04
45	OMEPRAZOLE	1,286,395	\$15,026,835	\$6,201,055	\$21,227,891	\$16.50
46	DULOXETINE	1,260,716	\$18,075,834	\$6,096,634	\$24,172,468	\$19.17
47	PREDNISOLONE	1,260,685	\$13,240,340	\$5,915,300	\$19,155,640	\$15.19
48	AMOXICILLIN + CLAVULANIC ACID	1,252,933	\$13,230,974	\$6,617,310	\$19,848,284	\$15.84
49	MACROGOL-3350 + SODIUM CHLORIDE + BICARBONATE + POTASSIUM CHLORIDE	1,252,544	\$20,208,529	\$5,222,818	\$25,431,347	\$20.30
50	DESVENLAFAXINE	1,216,877	\$24,582,780	\$8,316,370	\$32,899,150	\$27.04

* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 5(c): Top 25 PBS Antineoplastic Drugs (by Active Ingredient) Sorted by Highest Government Cost, 2021-22

Section 85 and Section 100, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	PEMBROLIZUMAB	50,296	\$427,011,809	\$235,725	\$427,247,534	\$8,494.66
2	NIVOLUMAB	51,323	\$395,640,907	\$261,418	\$395,902,325	\$7,713.94
3	LENALIDOMIDE	43,723	\$240,149,272	\$887,896	\$241,037,169	\$5,512.82
4	IPILIMUMAB	7,595	\$151,785,659	\$80,146	\$151,865,805	\$19,995.50
5	ATEZOLIZUMAB	17,779	\$132,723,584	\$105,848	\$132,829,432	\$7,471.14
6	IBRUTINIB	14,111	\$130,265,093	\$200,626	\$130,465,719	\$9,245.67
7	OSIMERTINIB	15,078	\$119,661,656	\$305,388	\$119,967,044	\$7,956.43
8	ENZALUTAMIDE	32,235	\$113,265,152	\$388,160	\$113,653,311	\$3,525.77
9	DARATUMUMAB	12,861	\$96,395,347	\$128,911	\$96,524,258	\$7,505.19
10	PALBOCICLIB	22,300	\$93,836,791	\$431,942	\$94,268,733	\$4,227.30
11	RIBOCICLIB	16,182	\$74,117,965	\$323,217	\$74,441,182	\$4,600.25
12	TRASTUZUMAB	62,071	\$70,647,722	\$814,842	\$71,462,564	\$1,151.30
13	RUXOLITINIB	15,020	\$69,903,032	\$240,094	\$70,143,126	\$4,669.98
14	DURVALUMAB	10,570	\$68,163,524	\$39,536	\$68,203,059	\$6,452.51
15	GOSERELIN^	123,018	\$65,895,449	\$2,920,606	\$68,816,056	\$559.40
16	VENETOCLAX	9,011	\$63,528,315	\$153,857	\$63,682,172	\$7,067.16
17	PERTUZUMAB	19,602	\$61,358,116	\$147,361	\$61,505,478	\$3,137.71
18	OBINUTUZUMAB	11,380	\$59,194,924	\$50,072	\$59,244,996	\$5,206.06
19	ABIRATERONE	16,843	\$57,703,039	\$205,188	\$57,908,227	\$3,438.12
20	BEVACIZUMAB	58,282	\$55,775,412	\$382,260	\$56,157,672	\$963.55
21	LEUPRORELIN^^	50,716	\$52,187,478	\$682,379	\$52,869,857	\$1,042.47
22	DASATINIB	13,530	\$49,892,390	\$365,509	\$50,257,899	\$3,714.55
23	POMALIDOMIDE	4,985	\$45,685,727	\$79,050	\$45,764,777	\$9,180.50
24	CARFILZUMIB	17,191	\$42,170,473	\$52,955	\$42,223,428	\$2,456.14
25	TRASTUZUMAB EMTANSINE	9,660	\$41,857,983	\$53,208	\$41,911,190	\$4,338.63

* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

^ Some of the usage may be for treating other conditions.

^^ Excludes PBS items that are not for cancer treatment.

Table 5(d): Top 25 PBS Biological Products and Medicines Sorted by Highest Government Cost, 2021-22

Section 85 and Section 100, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	AFLIBERCEPT	404,089	\$481,028,749	\$6,378,324	\$487,407,073	\$1,206.19
2	PEMBROLIZUMAB	50,296	\$427,011,809	\$235,725	\$427,247,534	\$8,494.66
3	NIVOLUMAB	51,323	\$395,640,907	\$261,418	\$395,902,325	\$7,713.94
4	USTEKINUMAB	42,062	\$300,245,114	\$1,285,837	\$301,530,951	\$7,168.73
5	ADALIMUMAB	304,799	\$273,394,919	\$8,718,161	\$282,113,080	\$925.57
6	DENOSUMAB	1,008,022	\$253,150,145	\$12,133,915	\$265,284,060	\$263.17
7	OCRELIZUMAB	11,169	\$194,040,084	\$377,848	\$194,417,932	\$17,406.92
8	RANIBIZUMAB	163,599	\$189,491,815	\$2,274,430	\$191,766,245	\$1,172.17
9	DUPILUMAB	92,352	\$157,758,778	\$2,882,354	\$160,641,131	\$1,739.44
10	IPILIMUMAB	7,595	\$151,785,659	\$80,146	\$151,865,805	\$19,995.50
11	ATEZOLIZUMAB	17,779	\$132,723,584	\$105,848	\$132,829,432	\$7,471.14
12	ETANERCEPT	104,685	\$107,681,654	\$2,433,871	\$110,115,526	\$1,051.87
13	VEDOLIZUMAB	37,665	\$104,140,849	\$1,272,375	\$105,413,224	\$2,798.70
14	INFLIXIMAB	75,912	\$103,191,081	\$2,618,924	\$105,810,004	\$1,393.85
15	SEMAGLUTIDE	858,460	\$96,985,456	\$17,197,649	\$114,183,105	\$133.01
16	DARATUMUMAB	12,861	\$96,395,347	\$128,911	\$96,524,258	\$7,505.19
17	GUSELKUMAB	25,090	\$94,475,719	\$772,610	\$95,248,328	\$3,796.27
18	SECUKINUMAB	63,551	\$86,383,152	\$1,800,328	\$88,183,481	\$1,387.60
19	GOLIMUMAB	74,074	\$83,896,729	\$2,075,519	\$85,972,248	\$1,160.63
20	DARBEPOETIN ALFA	72,836	\$78,995,201	\$1,044,225	\$80,039,426	\$1,098.90
21	TRASTUZUMAB	62,071	\$70,647,722	\$814,842	\$71,462,564	\$1,151.30
22	DURVALUMAB	10,570	\$68,163,524	\$39,536	\$68,203,059	\$6,452.51
23	INSULIN GLARGINE	331,114	\$67,742,225	\$4,992,779	\$72,735,004	\$219.67
24	FOLLITROPIN ALFA	51,607	\$61,615,169	\$2,066,778	\$63,681,947	\$1,233.98
25	PERTUZUMAB	19,602	\$61,358,116	\$147,361	\$61,505,478	\$3,137.71

* Total Cost includes cost to the patient and cost to the Government for PBS (\$85 + \$100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 6: Top 50 PBS Drugs (by Active Ingredient) Sorted by Highest Total Prescription Volume, 2021-22
 Section 85 and Section 100, including Drs Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Government Cost
1	ROSUVASTATIN	9,095,870	6,110,674	15,206,544	\$94,813,550
2	ATORVASTATIN	7,971,415	3,849,225	11,820,640	\$80,681,721
3	PANTOPRAZOLE	6,636,707	3,006,478	9,643,185	\$64,467,338
4	ESOMEPRAZOLE	5,702,279	2,541,169	8,243,448	\$81,392,899
5	PERINDOPRIL	4,154,721	2,783,219	6,937,940	\$42,443,122
6	ESCITALOPRAM	2,373,466	3,440,884	5,814,350	\$22,726,766
7	METFORMIN	3,555,331	2,071,389	5,626,720	\$41,496,824
8	SERTRALINE	2,412,280	3,020,291	5,432,571	\$22,760,672
9	AMLODIPINE	3,075,028	1,519,789	4,594,817	\$26,332,074
10	CEFALEXIN	2,172,083	2,354,086	4,526,169	\$20,568,164
11	TELMISARTAN	2,508,183	1,850,346	4,358,529	\$25,537,125
12	IRBESARTAN	2,670,202	1,397,441	4,067,643	\$25,878,869
13	PREGABALIN	3,098,435	862,416	3,960,851	\$55,950,444
14	CANDESARTAN	2,402,814	1,548,755	3,951,569	\$23,805,555
15	AMOXICILLIN	1,458,467	2,441,091	3,899,558	\$13,792,779
16	SALBUTAMOL	2,722,818	881,811	3,604,629	\$47,360,695
17	VENLAFAXINE	1,838,819	1,599,058	3,437,877	\$22,260,216
18	RAMIPRIL	2,103,325	1,241,446	3,344,771	\$20,221,798
19	APIXABAN	3,322,445	1,087	3,323,532	\$270,690,520
20	PARACETAMOL + CODEINE	1,971,330	1,293,741	3,265,071	\$35,587,249
21	MIRTAZAPINE	2,282,051	918,265	3,200,316	\$26,266,137
22	OXYCODONE	1,990,877	1,059,662	3,050,539	\$47,138,783
23	PERINDOPRIL + AMLODIPINE	1,616,435	1,404,841	3,021,276	\$18,922,376
24	ATENOLOL	2,044,537	836,320	2,880,857	\$18,754,875
25	AMOXICILLIN + CLAVULANIC ACID	1,252,933	1,590,319	2,843,252	\$13,230,974
26	AMITRIPTYLINE	1,745,798	1,015,279	2,761,077	\$18,612,682
27	FLUOXETINE	1,155,754	1,454,421	2,610,175	\$15,969,453
28	RABEPRAZOLE	1,713,267	879,932	2,593,199	\$17,634,328
29	METOPROLOL TARTRATE	1,846,006	623,632	2,469,638	\$17,876,565
30	MELOXICAM	1,338,328	1,130,238	2,468,566	\$14,487,635
31	RIVAROXABAN	2,439,138	1,476	2,440,614	\$162,827,092
32	DESVENLAFAXINE	1,216,877	1,193,549	2,410,426	\$24,582,780
33	LERCANIDIPINE	1,714,888	619,728	2,334,616	\$17,812,723
34	PREDNISOLONE	1,260,685	1,032,815	2,293,500	\$13,240,340
35	DIAZEPAM	1,486,929	792,819	2,279,748	\$12,546,963
36	CLOPIDOGREL	1,819,062	449,406	2,268,468	\$21,521,540
37	BISOPROLOL	1,603,556	559,451	2,163,007	\$25,400,105
38	DULOXETINE	1,260,716	861,638	2,122,354	\$18,075,834
39	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	2,084,796	16,137	2,100,933	\$69,927,078
40	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,391,708	688,167	2,079,875	\$14,767,395
41	SIMVASTATIN	1,613,766	462,694	2,076,460	\$15,218,170
42	DOXYCYCLINE	932,292	1,134,986	2,067,278	\$9,125,103
43	FLUTICASONE PROPIONATE + SALMETEROL	2,021,562	396	2,021,958	\$77,400,384
44	LEVOTHYROXINE	1,065,498	880,974	1,946,472	\$21,834,242
45	OMEPRAZOLE	1,286,395	558,226	1,844,621	\$15,026,835
46	DUTASTERIDE + TAMSULOSIN	1,503,918	337,237	1,841,155	\$38,489,130
47	GLICLAZIDE	1,355,465	477,979	1,833,444	\$20,128,839
48	CELECOXIB	980,556	852,023	1,832,579	\$11,753,458
49	TELMISARTAN + HYDROCHLOROTHIAZIDE	1,096,429	687,134	1,783,563	\$12,975,262
50	CITALOPRAM	972,752	805,080	1,777,832	\$8,857,537

Table 7: Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2021-22
 Section 85 and Section 100, including Drs Bag and under co-payment prescriptions

Rank	ATC Level 2 Code	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	24,464,711	15,856,513	40,321,224
2	C10	LIPID MODIFYING AGENTS	23,708,355	12,748,854	36,457,209
3	N06	PSYCHOANALEPTICS	19,432,080	15,871,281	35,303,361
4	A02	DRUGS FOR ACID RELATED DISORDERS	16,073,892	7,379,182	23,453,074
5	N02	ANALGESICS	15,215,596	5,565,986	20,781,582
6	J01	ANTIBACTERIALS FOR SYSTEMIC USE	8,718,622	10,463,072	19,181,694
7	A10	DRUGS USED IN DIABETES	15,124,784	2,622,481	17,747,265
8	R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	11,721,957	1,533,563	13,255,520
9	B01	ANTITHROMBOTIC AGENTS	9,945,727	895,991	10,841,718
10	C07	BETA BLOCKING AGENTS	6,890,414	2,513,526	9,403,940
11	C08	CALCIUM CHANNEL BLOCKERS	6,578,705	2,796,387	9,375,092
12	N05	PSYCHOLEPTICS	7,048,645	1,853,928	8,902,573
13	S01	OPHTHALMOLOGICALS	7,089,601	1,762,657	8,852,258
14	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,389,787	3,082,573	6,472,360
15	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	2,217,544	3,137,853	5,355,397
16	D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,274,238	1,772,008	4,046,246
17	H02	CORTICOSTEROIDS FOR SYSTEMIC USE	2,077,392	1,872,663	3,950,055
18	C01	CARDIAC THERAPY	2,887,064	650,031	3,537,095
19	N03	ANTIEPILEPTICS	2,509,545	844,394	3,353,939
20	C03	DIURETICS	2,508,435	595,387	3,103,822
21	C02	ANTIHYPERTENSIVES	2,137,195	646,999	2,784,194
22	G04	UROLOGICALS	2,048,127	454,332	2,502,459
23	M04	ANTIGOUT PREPARATIONS	1,335,457	949,218	2,284,675
24	L04	IMMUNOSUPPRESSANTS	2,045,682	146,071	2,191,753
25	M05	DRUGS FOR TREATMENT OF BONE DISEASES	1,906,849	248,407	2,155,256
26	H03	THYROID THERAPY	1,171,738	936,282	2,108,020
27	L01	ANTINEOPLASTIC AGENTS	1,991,304	102,720	2,094,024
28	N04	ANTI-PARKINSON DRUGS	1,403,835	214,541	1,618,376
29	J05	ANTIVIRALS FOR SYSTEMIC USE	1,047,600	524,669	1,572,269
30	A06	DRUGS FOR CONSTIPATION	1,414,882	84,226	1,499,108
31	A04	ANTIEMETICS AND ANTINAUSEANTS	879,540	464,368	1,343,908
32	B03	ANTIANGEMIC PREPARATIONS	1,060,678	128,795	1,189,473
33	L02	ENDOCRINE THERAPY	848,126	339,366	1,187,492
34	A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	765,623	354,677	1,120,300
35	S02	OTOLOGICALS	522,041	516,074	1,038,115
36	A07	ANTIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	907,748	42,143	949,891
37	N07	OTHER NERVOUS SYSTEM DRUGS	469,514	5,001	474,515
38	D10	ANTI-ACNE PREPARATIONS	259,683	177,404	437,087
39	A12	MINERAL SUPPLEMENTS	337,786	56,630	394,416
40	M03	MUSCLE RELAXANTS	310,102	71,251	381,353
41	D05	ANTIPSORIATICS	263,252	56,213	319,465
42	D11	OTHER DERMATOLOGICAL PREPARATIONS	140,605	86,847	227,452
43	G02	OTHER GYNECOLOGICALS	218,592	6,328	224,920
44	A09	DIGESTIVES, INCL. ENZYMES	193,840	824	194,664
45	A11	VITAMINS	146,635	40,577	187,212
46	H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	177,367	194	177,561
47	L03	IMMUNOSTIMULANTS	159,415	564	159,979
48	B02	ANTIHEMORRHAGICS	60,018	87,682	147,700
49	A01	STOMATOLOGICAL PREPARATIONS	82,945	42,487	125,432
50	V03	ALL OTHER THERAPEUTIC PRODUCTS	113,315	8,058	121,373

Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2020-21 and 2021-22

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution***			
	2020-21	2021-22	Prescriptions Change	Percentage Change	2020-21	2021-22	Gov Cost Change	Percentage Change	2020-21	2021-22	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	34,754,213	35,986,248	1,232,035	3.5%	\$1,085,577,962	\$1,206,835,981	\$121,258,019	11.2%	\$275,879,491	\$305,676,240	\$29,796,748	10.8%
BLOOD AND BLOOD FORMING ORGANS	10,799,376	11,068,172	268,796	2.5%	\$812,083,876	\$872,418,076	\$60,334,200	7.4%	\$114,399,961	\$124,301,567	\$9,901,606	8.7%
CARDIOVASCULAR SYSTEM	68,236,696	69,177,519	940,823	1.4%	\$1,080,274,114	\$1,126,986,515	\$46,712,401	4.3%	\$350,539,549	\$364,628,741	\$14,089,192	4.0%
DERMATOLOGICALS	3,130,983	3,033,533	-97,450	-3.1%	\$97,822,994	\$211,218,785	\$113,395,790	115.9%	\$30,625,498	\$32,554,892	\$1,929,394	6.3%
GENITO URINARY SYSTEM AND SEX HORMONES	4,461,794	4,484,263	22,469	0.5%	\$296,884,861	\$295,676,149	-\$1,208,713	-0.4%	\$42,826,875	\$43,991,776	\$1,164,901	2.7%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,558,495	3,523,523	-34,972	-1.0%	\$192,396,947	\$189,580,238	-\$2,816,709	-1.5%	\$22,826,362	\$23,107,660	\$281,299	1.2%
ANTIINFECTIVES FOR SYSTEMIC USE	10,198,228	9,878,509	-319,719	-3.1%	\$839,302,784	\$789,663,627	-\$49,639,156	-5.9%	\$70,123,974	\$70,393,857	\$269,884	0.4%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	4,801,131	5,044,527	243,396	5.1%	\$5,647,097,599	\$6,081,268,457	\$434,170,858	7.7%	\$74,799,907	\$83,542,129	\$8,742,222	11.7%
MUSCULO-SKELETAL SYSTEM	7,071,789	6,943,075	-128,714	-1.8%	\$472,626,660	\$478,783,424	\$6,156,764	1.3%	\$45,365,873	\$46,061,159	\$695,286	1.5%
NERVOUS SYSTEM	46,818,787	46,099,364	-719,423	-1.5%	\$1,297,889,505	\$1,319,210,204	\$21,320,699	1.6%	\$291,441,906	\$299,590,050	\$8,148,145	2.8%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	65,086	59,835	-5,251	-8.1%	\$2,987,973	\$3,235,886	\$247,913	8.3%	\$448,565	\$456,578	\$8,013	1.8%
RESPIRATORY SYSTEM	11,763,002	11,805,911	42,909	0.4%	\$890,451,081	\$982,249,177	\$91,798,096	10.3%	\$138,477,632	\$151,578,544	\$13,100,912	9.5%
SENSORY ORGANS	7,616,065	7,626,801	10,736	0.1%	\$779,082,684	\$822,801,110	\$43,718,426	5.6%	\$42,500,770	\$42,655,031	\$154,261	0.4%
VARIOUS	191,756	188,351	-3,405	-1.8%	\$74,565,355	\$66,736,763	-\$7,828,592	-10.5%	\$3,292,398	\$3,379,864	\$87,466	2.7%
UNLESS OTHERWISE CLASSIFIED	119,271	98,087	-21,184	-17.8%	\$4,411,850	\$3,903,305	-\$508,545	-11.5%	\$782,509	\$662,540	-\$119,970	-15.3%
TOTAL	213,586,672	215,017,718	1,431,046	0.7%	\$13,573,456,246	\$14,450,567,697	\$877,111,451	6.5%	\$1,504,331,268	\$1,592,580,628	\$88,249,360	5.9%

ATC Group Level 1	Total Cost*				Average Price**			
	2020-21	2021-22	Total Cost Change	Percentage Change	2020-21	2021-22	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$1,361,457,453	\$1,512,512,220	\$151,054,767	11.1%	\$39.17	\$42.03	\$2.86	7.3%
BLOOD AND BLOOD FORMING ORGANS	\$926,483,837	\$996,719,642	\$70,235,806	7.6%	\$85.79	\$90.05	\$4.26	5.0%
CARDIOVASCULAR SYSTEM	\$1,430,813,663	\$1,491,615,256	\$60,801,593	4.2%	\$20.97	\$21.56	\$0.59	2.8%
DERMATOLOGICALS	\$128,448,492	\$243,773,676	\$115,325,184	89.8%	\$41.02	\$80.36	\$39.34	95.9%
GENITO URINARY SYSTEM AND SEX HORMONES	\$339,711,737	\$339,667,925	-\$43,812	0.0%	\$76.14	\$75.75	-\$0.39	-0.5%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$215,223,309	\$212,687,898	-\$2,535,410	-1.2%	\$60.48	\$60.36	-\$0.12	-0.2%
ANTIINFECTIVES FOR SYSTEMIC USE	\$909,426,757	\$860,057,485	-\$49,369,273	-5.4%	\$89.17	\$87.06	-\$2.11	-2.4%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$5,721,897,506	\$6,164,810,585	\$442,913,080	7.7%	\$1,191.78	\$1,222.08	\$30.30	2.5%
MUSCULO-SKELETAL SYSTEM	\$517,992,533	\$524,844,583	\$6,852,050	1.3%	\$73.25	\$75.59	\$2.34	3.2%
NERVOUS SYSTEM	\$1,589,331,411	\$1,618,800,254	\$29,468,844	1.9%	\$33.95	\$35.12	\$1.17	3.4%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$3,436,538	\$3,692,464	\$255,926	7.4%	\$52.80	\$61.71	\$8.91	16.9%
RESPIRATORY SYSTEM	\$1,028,928,713	\$1,133,827,721	\$104,899,009	10.2%	\$87.47	\$96.04	\$8.57	9.8%
SENSORY ORGANS	\$821,583,454	\$865,456,141	\$43,872,688	5.3%	\$107.88	\$113.48	\$5.60	5.2%
VARIOUS	\$77,857,753	\$70,116,627	-\$7,741,126	-9.9%	\$406.03	\$372.27	-\$33.76	-8.3%
UNLESS OTHERWISE CLASSIFIED	\$5,194,359	\$4,565,845	-\$628,515	-12.1%	\$43.55	\$46.55	\$3.00	6.9%
TOTAL	\$15,077,787,514	\$16,043,148,325	\$965,360,811	6.4%	\$70.59	\$74.61	\$4.02	5.7%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 9(a): Top 35 Drugs Sorted by Highest Change to Government Cost, 2020-21 and 2021-22
 Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2020-21					2021-22					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	DUPILUMAB	13,303	\$22,789,858	\$416,844	\$23,206,701	\$1,744	92,352	\$157,758,778	\$2,882,354	\$160,641,131	\$1,739	\$134,968,920	592.23%
2	SEMAGLUTIDE	186,260	\$21,025,580	\$3,722,342	\$24,747,922	\$133	858,460	\$96,985,456	\$17,197,649	\$114,183,105	\$133	\$75,959,877	361.27%
3	DARATUMUMAB	3,533	\$27,600,863	\$12,354	\$27,613,217	\$7,816	12,861	\$96,395,347	\$128,911	\$96,524,258	\$7,505	\$68,794,483	249.25%
4	OSIMERTINIB	7,703	\$61,144,802	\$153,669	\$61,298,471	\$7,958	15,078	\$119,661,656	\$305,388	\$119,967,044	\$7,956	\$58,516,854	95.70%
5	UPADACITINIB	28,059	\$35,201,220	\$627,281	\$35,828,500	\$1,277	73,379	\$91,927,542	\$1,767,626	\$93,695,167	\$1,277	\$56,726,322	161.15%
6	AFLIBERCEPT	349,785	\$425,108,204	\$5,389,406	\$430,497,610	\$1,231	404,089	\$481,028,749	\$6,378,324	\$487,407,073	\$1,206	\$55,920,544	13.15%
7	USTEKINUMAB	35,281	\$245,055,330	\$1,045,636	\$246,100,967	\$6,975	42,062	\$300,245,114	\$1,285,837	\$301,530,951	\$7,169	\$55,189,784	22.52%
8	IPILIMUMAB	4,290	\$103,943,513	\$45,141	\$103,988,654	\$24,240	7,595	\$151,785,659	\$80,146	\$151,865,805	\$19,996	\$47,842,146	46.03%
9	GALCANEZUMAB	2,657	\$2,487,660	\$79,127	\$2,566,787	\$966	59,428	\$40,075,121	\$1,739,339	\$41,814,460	\$704	\$37,587,461	1,510.96%
10	GUSELKUMAB	16,225	\$61,210,792	\$496,067	\$61,706,859	\$3,803	25,090	\$94,475,719	\$772,610	\$95,248,328	\$3,796	\$33,264,926	54.34%
11	APIXABAN	2,913,338	\$239,001,009	\$33,312,532	\$272,313,541	\$93	3,322,445	\$270,690,520	\$40,023,903	\$310,714,423	\$94	\$31,689,511	13.26%
12	VENETOCLAX	4,847	\$34,342,455	\$84,873	\$34,427,328	\$7,103	9,011	\$63,528,315	\$153,857	\$63,682,172	\$7,067	\$29,185,860	84.98%
13	LIPEGFILGRASTIM	16,429	\$19,018,911	\$394,918	\$19,413,829	\$1,182	39,006	\$45,103,521	\$1,053,333	\$46,156,854	\$1,183	\$26,084,610	137.15%
14	DULAGLUTIDE	541,619	\$62,892,685	\$8,690,498	\$71,583,183	\$132	753,874	\$88,046,248	\$11,645,871	\$99,692,119	\$132	\$25,153,563	39.99%
15	ATEZOLIZUMAB	14,557	\$108,216,462	\$85,017	\$108,301,478	\$7,440	17,779	\$132,723,584	\$105,848	\$132,829,432	\$7,471	\$24,507,122	22.65%
16	LENALIDOMIDE	39,622	\$216,334,206	\$746,988	\$217,081,195	\$5,479	43,723	\$240,149,272	\$887,896	\$241,037,169	\$5,513	\$23,815,066	11.01%
17	RISANKIZUMAB	5,359	\$28,745,985	\$166,746	\$28,912,731	\$5,395	9,363	\$50,195,326	\$297,294	\$50,492,620	\$5,393	\$21,449,341	74.62%
18	ACALABRUTINIB	1,190	\$9,747,522	\$16,081	\$9,763,603	\$8,205	3,751	\$30,725,532	\$52,349	\$30,777,882	\$8,205	\$20,978,010	215.21%
19	SACUBITRIL + VALSARTAN	437,624	\$83,200,709	\$5,646,967	\$88,847,676	\$203	543,501	\$102,929,230	\$7,431,297	\$110,360,527	\$203	\$19,728,521	23.71%
20	OCRELIZUMAB	10,080	\$175,153,740	\$329,443	\$175,483,183	\$17,409	11,169	\$194,040,084	\$377,848	\$194,417,932	\$17,407	\$18,886,344	10.78%
21	PALBOCICLIB	18,225	\$76,835,488	\$355,435	\$77,190,922	\$4,235	22,300	\$93,836,791	\$431,942	\$94,268,733	\$4,227	\$17,001,303	22.13%
22	VEDOLIZUMAB	28,563	\$87,301,339	\$937,405	\$88,238,744	\$3,089	37,665	\$104,140,849	\$1,272,375	\$105,413,224	\$2,799	\$16,839,511	19.29%
23	LISDEXAMFETAMINE	466,812	\$40,701,285	\$10,970,578	\$51,671,863	\$111	782,678	\$55,774,770	\$21,475,980	\$77,250,751	\$99	\$15,073,485	37.03%
24	CABOZANTINIB	2,321	\$23,287,822	\$39,616	\$23,327,438	\$10,051	3,520	\$34,973,252	\$60,478	\$35,033,729	\$9,953	\$11,685,430	50.18%
25	RIVAROXBAN	2,250,301	\$151,178,761	\$30,580,001	\$181,758,763	\$81	2,439,138	\$162,827,092	\$34,476,958	\$197,304,050	\$81	\$11,648,331	7.71%
26	EVOLOCUMAB	35,605	\$19,553,040	\$850,211	\$20,403,251	\$573	58,738	\$30,976,483	\$1,385,667	\$32,362,149	\$551	\$11,423,443	58.42%
27	BICTEGRAVIR + EMTRICITABINE + TENOFOVIR ALAFENAMIDE	51,440	\$91,432,041	\$1,480,908	\$92,912,949	\$1,806	57,417	\$102,196,234	\$1,727,686	\$103,923,920	\$1,810	\$10,764,193	11.77%
28	BENRALIZUMAB	13,115	\$43,728,543	\$287,616	\$44,016,159	\$3,356	16,214	\$54,062,424	\$372,176	\$54,434,600	\$3,357	\$10,333,880	23.63%
29	SELEXIPAG	758	\$4,492,974	\$14,851	\$4,507,825	\$5,947	3,259	\$14,734,281	\$62,599	\$14,796,880	\$4,540	\$10,241,307	227.94%
30	APREMILAST	4,335	\$2,453,276	\$117,778	\$2,571,054	\$593	20,554	\$12,399,555	\$578,107	\$12,977,662	\$631	\$9,946,279	405.43%
31	ABEMACICLIB	1,625	\$6,846,843	\$35,050	\$6,881,894	\$4,235	3,918	\$16,500,097	\$83,432	\$16,583,529	\$4,233	\$9,653,254	140.99%
32	INSULIN DEGLUDEC + INSULIN ASPART	133,486	\$47,941,638	\$1,584,997	\$49,526,635	\$371	160,163	\$57,402,066	\$1,952,455	\$59,354,521	\$371	\$9,460,427	19.73%
33	PEMBROLIZUMAB	48,063	\$417,588,335	\$216,008	\$417,804,343	\$8,693	50,296	\$427,011,809	\$235,725	\$427,247,534	\$8,495	\$9,423,474	2.26%
34	SIPONIMOD	2,339	\$4,480,858	\$46,903	\$4,527,761	\$1,936	6,588	\$13,847,079	\$123,334	\$13,970,413	\$2,121	\$9,366,222	209.03%
35	DOLUTEGRAVIR + LAMIVUDINE	3,738	\$5,117,718	\$118,416	\$5,236,134	\$1,401	9,942	\$13,656,670	\$331,068	\$13,987,738	\$1,407	\$8,538,953	166.85%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 9(b): Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2020-21 and 2021-22
 Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2020-21					2021-22					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	SEMAGLUTIDE	186,260	\$21,025,580	\$3,722,342	\$24,747,922	\$132.87	858,460	\$96,985,456	\$17,197,649	\$114,183,105	\$133.01	672,200	360.89%
2	ROSUVASTATIN	8,591,250	\$96,496,980	\$43,568,750	\$140,065,730	\$16.30	9,095,870	\$94,813,550	\$46,903,517	\$141,717,066	\$15.58	504,620	5.87%
3	APIXABAN	2,913,338	\$239,001,009	\$33,312,532	\$272,313,541	\$93.47	3,322,445	\$270,690,520	\$40,023,903	\$310,714,423	\$93.52	409,107	14.04%
4	LISDEXAMFETAMINE	466,812	\$40,701,285	\$10,970,578	\$51,671,863	\$110.69	782,678	\$55,774,770	\$21,475,980	\$77,250,751	\$98.70	315,866	67.66%
5	PANTOPRAZOLE	6,397,830	\$61,973,544	\$30,215,060	\$92,188,605	\$14.41	6,636,707	\$64,467,338	\$31,850,784	\$96,318,121	\$14.51	238,877	3.73%
6	DULAGLUTIDE	541,619	\$62,892,685	\$8,690,498	\$71,583,183	\$132.17	753,874	\$88,046,248	\$11,645,871	\$99,692,119	\$132.24	212,255	39.19%
7	RIVAROXABAN	2,250,301	\$151,178,761	\$30,580,001	\$181,758,763	\$80.77	2,439,138	\$162,827,092	\$34,476,958	\$197,304,050	\$80.89	188,837	8.39%
8	DEXAMETHASONE	376,962	\$15,122,577	\$2,081,264	\$17,203,841	\$45.64	542,478	\$22,325,660	\$2,912,079	\$25,237,739	\$46.52	165,516	43.91%
9	EMPAGLIFLOZIN	1,057,727	\$46,958,598	\$16,531,413	\$63,490,010	\$60.02	1,216,647	\$53,543,265	\$19,519,731	\$73,062,996	\$60.05	158,920	15.02%
10	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,930,651	\$67,816,662	\$37,091,523	\$104,908,185	\$54.34	2,084,796	\$69,927,078	\$43,919,307	\$113,846,384	\$54.61	154,145	7.98%
11	EMPAGLIFLOZIN + METFORMIN	807,591	\$35,772,223	\$14,966,438	\$50,738,661	\$62.83	936,118	\$40,868,483	\$17,961,772	\$58,830,254	\$62.84	128,527	15.91%
12	DUTASTERIDE + TAMSULOSIN	1,375,889	\$37,106,110	\$6,425,760	\$43,531,870	\$31.64	1,503,918	\$38,489,130	\$7,148,719	\$45,637,849	\$30.35	128,029	9.31%
13	BISOPROLOL	1,483,995	\$23,580,750	\$6,745,500	\$30,326,250	\$20.44	1,603,556	\$25,400,105	\$7,397,633	\$32,797,738	\$20.45	119,561	8.06%
14	NIZATIDINE	195,909	\$3,523,347	\$871,025	\$4,394,372	\$22.43	305,175	\$5,522,307	\$1,348,526	\$6,870,833	\$22.51	109,266	55.77%
15	SACUBITRIL + VALSARTAN	437,624	\$83,200,709	\$5,646,967	\$88,847,676	\$203.02	543,501	\$102,929,230	\$7,431,297	\$110,360,527	\$203.05	105,877	24.19%
16	HYALURONATE SODIUM	417,142	\$12,691,965	\$1,854,629	\$14,546,594	\$34.87	519,097	\$15,747,393	\$2,356,901	\$18,104,294	\$34.88	101,955	24.44%
17	DAPAGLIFLOZIN	591,623	\$24,344,478	\$9,270,167	\$33,614,645	\$56.82	693,101	\$28,411,844	\$10,982,138	\$39,393,982	\$56.84	101,478	17.15%
18	FLUTICASON FUROATE + UMECLIDINIUM + VILANTEROL	511,674	\$43,723,332	\$4,709,993	\$48,433,326	\$94.66	605,992	\$49,202,122	\$5,860,294	\$55,062,415	\$90.86	94,318	18.43%
19	METHYLPHENIDATE	863,326	\$32,984,120	\$15,640,918	\$48,625,037	\$56.32	954,217	\$35,196,653	\$18,441,418	\$53,638,070	\$56.21	90,891	10.53%
20	AMLODIPINE	2,985,730	\$25,201,202	\$14,584,647	\$39,785,849	\$13.33	3,075,028	\$26,332,074	\$15,290,236	\$41,622,311	\$13.54	89,298	2.99%
21	ATORVASTATIN	7,882,469	\$79,190,760	\$38,582,023	\$117,772,783	\$14.94	7,971,415	\$80,681,721	\$39,722,038	\$120,403,760	\$15.10	88,946	1.13%
22	METFORMIN	3,470,670	\$40,319,719	\$15,499,112	\$55,818,831	\$16.08	3,555,331	\$41,496,824	\$16,130,368	\$57,627,192	\$16.21	84,661	2.44%
23	GUANFACINE	236,933	\$25,923,367	\$4,112,247	\$30,035,614	\$126.77	317,341	\$34,365,979	\$5,944,112	\$40,310,090	\$127.02	80,408	33.94%
24	DUPILUMAB	13,303	\$22,789,858	\$416,844	\$23,206,701	\$1,744.47	92,352	\$157,758,778	\$2,882,354	\$160,641,131	\$1,739.44	79,049	594.22%
25	TAPENTADOL	922,162	\$32,108,079	\$7,120,785	\$39,228,863	\$42.54	997,509	\$34,614,557	\$7,416,401	\$42,030,958	\$42.14	75,347	8.17%
26	CANDESARTAN	2,330,831	\$22,969,056	\$11,960,797	\$34,929,853	\$14.99	2,402,814	\$23,805,555	\$12,532,249	\$36,337,803	\$15.12	71,983	3.09%
27	DENOSUMAB	937,371	\$256,182,416	\$10,935,943	\$267,118,359	\$284.97	1,008,022	\$253,150,145	\$12,133,915	\$265,284,060	\$263.17	70,651	7.54%
28	EZETIMIBE + ATORVASTATIN	518,907	\$12,916,413	\$2,503,923	\$15,420,336	\$29.72	586,176	\$12,164,266	\$2,864,098	\$15,028,364	\$25.64	67,269	12.96%
29	EZETIMIBE	1,056,910	\$23,127,980	\$4,864,482	\$27,992,462	\$26.49	1,119,637	\$19,743,241	\$5,245,947	\$24,989,188	\$22.32	62,727	5.93%
30	MIRTAZAPINE	2,221,279	\$25,525,295	\$10,483,165	\$36,008,460	\$16.21	2,282,051	\$26,266,137	\$10,862,239	\$37,128,376	\$16.27	60,772	2.74%
31	GALCANEZUMAB	2,657	\$2,487,660	\$79,127	\$2,566,787	\$966.05	59,428	\$40,075,121	\$1,739,339	\$41,814,460	\$703.62	56,771	2,136.66%
32	AFLIBERCEPT	349,785	\$425,108,204	\$5,389,406	\$430,497,610	\$1,230.75	404,089	\$481,028,749	\$6,378,324	\$487,407,073	\$1,206.19	54,304	15.52%
33	BUPROPION	23,759	\$2,155,417	\$547,034	\$2,702,450	\$113.74	76,180	\$6,648,271	\$1,964,531	\$8,612,801	\$113.06	52,421	220.64%
34	LINAGLIPTIN	668,443	\$33,757,072	\$6,654,785	\$40,411,857	\$60.46	720,025	\$36,087,381	\$7,469,827	\$43,557,208	\$60.49	51,582	7.72%
35	TELMISARTAN	2,456,916	\$24,860,428	\$12,839,099	\$37,699,527	\$15.34	2,508,183	\$25,537,125	\$13,303,023	\$38,840,148	\$15.49	51,267	2.09%

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 10(a): PBS Section 85 Prescription Volume, 2018-19 to 2021-22
Section 85 only, including Drs Bag and under co-payment prescriptions

Prescription Type	2018-19	2019-20	2020-21	2021-22
Over Co-payment	202,303,331	205,491,355	210,342,870	211,674,057
Under Co-payment	93,869,490	96,326,979	93,541,931	100,742,083
Total	296,172,821	301,818,334	303,884,801	312,416,140





Table 10(b): PBS Section 85 expenditure, 2018-19 to 2021-22
Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Expenditure Type	2018-19	2019-20	2020-21	2021-22
Government Cost	\$8,211,605,634	\$8,552,509,975	\$9,136,913,351	\$9,872,792,641
Patient Contribution*	\$1,440,201,572	\$1,471,119,001	\$1,450,387,202	\$1,534,376,869
Total Cost**	\$9,651,807,207	\$10,023,628,976	\$10,587,300,553	\$11,407,169,510



* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

** Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

Table 11: PBS Prescriptions and Government Cost by Formulary, 2021-22

Section 85 and Section 100, including under co-payment prescriptions and Drs Bag

Formulary Group ¹	PBS Subsidised Prescriptions	Under co-payment Prescriptions	Total Prescriptions	Percentage	Government Cost	Percentage
F1	27,897,700	3,049,481	30,947,181	9.8%	\$8,859,214,113	61.3%
F2	177,036,727	96,894,714	273,931,441	86.7%	\$4,456,734,119	30.8%
Combination Drugs ²	9,980,856	821,964	10,802,820	3.4%	\$1,130,591,969	7.8%
Other ³	102,435	24,261	126,696	0.0%	\$4,027,496	0.0%
Total	215,017,718	100,790,420	315,808,138	100.0%	\$14,450,567,697	100.0%

Notes:

1. The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2. Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands. Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply. Allocation to F1 or F2 is determined by legislative instrument.
2. Combination Drugs are not allocated to any formulary.
3. The category 'Other' includes extemporaneously prepared items.

Table 12(a): Top 20 Responsible Persons by Total Cost, 2021-22

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,163,026	1,847,681	7,010,707	\$1,043,452,802	\$50,194,837	\$1,093,647,640	\$912,856,348
2	JANSSEN-CILAG PTY LTD	1,968,945	351,635	2,320,580	\$1,009,985,967	\$25,538,030	\$1,035,523,997	\$878,133,078
3	APOTEX PTY LTD	43,074,763	20,435,221	63,509,984	\$591,296,918	\$219,099,443	\$810,396,361	\$315,863,086
4	BAYER AUSTRALIA LTD	3,410,184	779,831	4,190,015	\$711,316,263	\$51,066,467	\$762,382,729	\$657,239,117
5	ABBVIE PTY LTD	394,565	12	394,577	\$652,989,051	\$10,405,949	\$663,395,000	\$606,425,932
6	ALPHAPHARM PTY LTD	32,003,366	16,897,906	48,901,272	\$481,866,438	\$166,763,492	\$648,629,930	\$300,518,350
7	ASTRAZENECA PTY LTD	6,448,451	1,521,408	7,969,859	\$504,979,397	\$88,903,634	\$593,883,031	\$452,452,695
8	BOEHRINGER INGELHEIM PTY LTD	8,067,502	1,645,328	9,712,830	\$342,448,385	\$89,697,548	\$432,145,932	\$319,935,152
9	ROCHE PRODUCTS PTY LTD	598,258	63,855	662,113	\$412,906,470	\$7,039,933	\$419,946,403	\$357,945,220
10	AMGEN AUSTRALIA PTY LIMITED	1,185,664	85	1,185,749	\$402,140,614	\$15,701,942	\$417,842,556	\$331,108,596
11	PFIZER AUSTRALIA PTY LTD	2,557,090	1,529,892	4,086,982	\$381,023,576	\$28,292,762	\$409,316,338	\$362,272,086
12	SANDOZ PTY LTD	17,534,165	19,767,857	37,302,022	\$301,320,197	\$103,912,822	\$405,233,019	\$240,489,897
13	SANOFI-AVENTIS AUSTRALIA PTY LTD	6,365,904	2,660,703	9,026,607	\$352,271,908	\$43,988,380	\$396,260,288	\$285,225,492
14	ARROW PHARMA PTY LTD	18,855,541	8,282,035	27,137,576	\$293,390,178	\$95,244,304	\$388,634,482	\$172,186,350
15	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,426,395	1,361	3,427,756	\$346,154,523	\$41,984,803	\$388,139,325	\$322,505,945
16	VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD.	19,019	-	19,019	\$374,474,773	\$302,223	\$374,776,996	\$358,299,633
17	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,235,481	1,054,762	7,290,243	\$271,372,663	\$74,294,523	\$345,667,187	\$231,100,519
18	GILEAD SCIENCES PTY LIMITED	128,590	-	128,590	\$312,140,577	\$3,794,773	\$315,935,350	\$309,675,462
19	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	2,940,943	688,727	3,629,670	\$268,005,013	\$42,391,852	\$310,396,865	\$219,359,235
20	NOVO NORDISK PHARMACEUTICALS PTY. LIMITED	1,950,951	302,741	2,253,692	\$278,049,372	\$31,211,380	\$309,260,752	\$267,911,381

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 12(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2021-22

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	APOTEX PTY LTD	43,074,763	20,435,221	63,509,984	\$591,296,918	\$219,099,443	\$810,396,361	\$315,863,086
2	ALPHAPHARM PTY LTD	32,003,366	16,897,906	48,901,272	\$481,866,438	\$166,763,492	\$648,629,930	\$300,518,350
3	ARROW PHARMA PTY LTD	18,855,541	8,282,035	27,137,576	\$293,390,178	\$95,244,304	\$388,634,482	\$172,186,350
4	SANDOZ PTY LTD	17,534,165	19,767,857	37,302,022	\$301,320,197	\$103,912,822	\$405,233,019	\$240,489,897
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	11,362,017	7,286,899	18,648,916	\$173,048,424	\$61,904,305	\$234,952,729	\$125,386,162
6	BOEHRINGER INGELHEIM PTY LTD	8,067,502	1,645,328	9,712,830	\$342,448,385	\$89,697,548	\$432,145,932	\$319,935,152
7	ASTRAZENECA PTY LTD	6,448,451	1,521,408	7,969,859	\$504,979,397	\$88,903,634	\$593,883,031	\$452,452,695
8	SANOFI-AVENTIS AUSTRALIA PTY LTD	6,365,904	2,660,703	9,026,607	\$352,271,908	\$43,988,380	\$396,260,288	\$285,225,492
9	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,235,481	1,054,762	7,290,243	\$271,372,663	\$74,294,523	\$345,667,187	\$231,100,519
10	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,163,026	1,847,681	7,010,707	\$1,043,452,802	\$50,194,837	\$1,093,647,640	\$912,856,348
11	SERVIER LABORATORIES (AUST.) PTY. LTD.	3,479,774	2,168,786	5,648,560	\$53,947,223	\$19,171,615	\$73,118,838	\$38,031,788
12	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,426,395	1,361	3,427,756	\$346,154,523	\$41,984,803	\$388,139,325	\$322,505,945
13	BAYER AUSTRALIA LTD	3,410,184	779,831	4,190,015	\$711,316,263	\$51,066,467	\$762,382,729	\$657,239,117
14	MUNDIPHARMA PTY LIMITED	3,174,239	491,293	3,665,532	\$147,774,889	\$24,285,529	\$172,060,418	\$117,243,333
15	MYLAN HEALTH PTY LTD	3,148,405	1,403,676	4,552,081	\$78,836,647	\$17,556,575	\$96,393,222	\$65,693,111
16	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	2,940,943	688,727	3,629,670	\$268,005,013	\$42,391,852	\$310,396,865	\$219,359,235
17	UPJOHN AUSTRALIA PTY LTD	2,712,769	2,138,308	4,851,077	\$43,702,590	\$13,958,363	\$57,660,953	\$33,208,396
18	PFIZER AUSTRALIA PTY LTD	2,557,090	1,529,892	4,086,982	\$381,023,576	\$28,292,762	\$409,316,338	\$362,272,086
19	A.MENARINI AUSTRALIA PTY LIMITED	2,314,736	1,311,261	3,625,997	\$41,374,331	\$15,387,770	\$56,762,101	\$30,522,942
20	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	2,251,946	2,139	2,254,085	\$160,039,730	\$35,512,757	\$195,552,487	\$155,504,263

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2021-22

Section 85 and Section 100 excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	APOTEX PTY LTD	43,074,763	20,435,221	63,509,984	\$591,296,918	\$219,099,443	\$810,396,361	\$315,863,086
2	ALPHAPHARM PTY LTD	32,003,366	16,897,906	48,901,272	\$481,866,438	\$166,763,492	\$648,629,930	\$300,518,350
3	SANDOZ PTY LTD	17,534,165	19,767,857	37,302,022	\$301,320,197	\$103,912,822	\$405,233,019	\$240,489,897
4	ARROW PHARMA PTY LTD	18,855,541	8,282,035	27,137,576	\$293,390,178	\$95,244,304	\$388,634,482	\$172,186,350
5	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	11,362,017	7,286,899	18,648,916	\$173,048,424	\$61,904,305	\$234,952,729	\$125,386,162
6	BOEHRINGER INGELHEIM PTY LTD	8,067,502	1,645,328	9,712,830	\$342,448,385	\$89,697,548	\$432,145,932	\$319,935,152
7	SANOVI-AVENTIS AUSTRALIA PTY LTD	6,365,904	2,660,703	9,026,607	\$352,271,908	\$43,988,380	\$396,260,288	\$285,225,492
8	ASTRAZENECA PTY LTD	6,448,451	1,521,408	7,969,859	\$504,979,397	\$88,903,634	\$593,883,031	\$452,452,695
9	GLAXOSMITHKLINE AUSTRALIA PTY LTD	6,235,481	1,054,762	7,290,243	\$271,372,663	\$74,294,523	\$345,667,187	\$231,100,519
10	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,163,026	1,847,681	7,010,707	\$1,043,452,802	\$50,194,837	\$1,093,647,640	\$912,856,348
11	SERVIER LABORATORIES (AUST.) PTY. LTD.	3,479,774	2,168,786	5,648,560	\$53,947,223	\$19,171,615	\$73,118,838	\$38,031,788
12	UPJOHN AUSTRALIA PTY LTD	2,712,769	2,138,308	4,851,077	\$43,702,590	\$13,958,363	\$57,660,953	\$33,208,396
13	MYLAN HEALTH PTY LTD	3,148,405	1,403,676	4,552,081	\$78,836,647	\$17,556,575	\$96,393,222	\$65,693,111
14	BAYER AUSTRALIA LTD	3,410,184	779,831	4,190,015	\$711,316,263	\$51,066,467	\$762,382,729	\$657,239,117
15	PFIZER AUSTRALIA PTY LTD	2,557,090	1,529,892	4,086,982	\$381,023,576	\$28,292,762	\$409,316,338	\$362,272,086
16	MUNDIPHARMA PTY LIMITED	3,174,239	491,293	3,665,532	\$147,774,889	\$24,285,529	\$172,060,418	\$117,243,333
17	TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.	2,940,943	688,727	3,629,670	\$268,005,013	\$42,391,852	\$310,396,865	\$219,359,235
18	A.MENARINI AUSTRALIA PTY LIMITED	2,314,736	1,311,261	3,625,997	\$41,374,331	\$15,387,770	\$56,762,101	\$30,522,942
19	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	3,426,395	1,361	3,427,756	\$346,154,523	\$41,984,803	\$388,139,325	\$322,505,945
20	JANSSEN-CILAG PTY LTD	1,968,945	351,635	2,320,580	\$1,009,985,967	\$25,538,030	\$1,035,523,997	\$878,133,078

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 13: Number of PBS Approved Suppliers, 30 June 2022

Pharmacy State	Number of Community Pharmacies	Number of Private Hospitals	Number of Public Hospitals (Pharmaceutical Reforms)	Number of Dispensing Doctors
NSW	1,916	49	-	1
VIC	1,407	37	70	1
QLD	1,191	42	52	-
SA	463	11	15	1
WA	647	6	22	4
TAS	155	5	4	1
NT	42	1	6	-
ACT	80	5	-	-
Total	5,901	156	169	8

Table 14: PBS Brand Premiums, 2021-22

Section 85 and Section 100, excluding Drs Bag and including under co-payment prescriptions

	2021-22
Number of brands listed on the PBS ^(a)	5,173
Number of brands with a premium ^(a)	379
% of brands with a premium	7.3%
Average brand premium	\$5.33
Weighted average brand premium ^(b)	\$4.55
Brand premium range	\$0.50 to \$35.30
Prescriptions (millions) dispensed on the PBS ^(c)	179.7
Prescriptions (millions) dispensed with a brand premium	34.5
% of prescriptions dispensed with a brand premium	19.2%

Notes:

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2022 PBS Schedule. Note this differs from cover page figure which includes Drs Bag.

(b) Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium

(c) Includes only items where at least one brand is listed with a premium.

Table 15(a) PBS/RPBS prescriptions dispensed by Community Pharmacies, 2021-22

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Prescription Type	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	46,788,429	24%	5,806,920	30%	1,068,058	15%	53,663,407	25%
Non-Discounted	145,201,865	76%	13,317,753	70%	6,053,283	85%	164,572,901	75%
Total	191,990,294	100%	19,124,673	100%	7,121,341	100%	218,236,308	100%

Table 15(b) PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2021-22

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Discount Range	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	45,689,983	97.7%	5,717,882	98.5%	1,038,258	97.2%	52,446,123	97.7%
0.50 - < \$1.00	681,079	1.5%	50,599	0.9%	17,134	1.6%	748,812	1.4%
< 50c	212,206	0.5%	15,234	0.3%	6,642	0.6%	234,082	0.4%
Other	205,161	0.4%	23,205	0.4%	6,024	0.6%	234,390	0.4%
Total	46,788,429	100.0%	5,806,920	100.0%	1,068,058	100.0%	53,663,407	100.0%

Table 16(a): PBS/RPBS Medicines Supplied under Continued Dispensing by Dispensing Pharmacy State, 2021-22

Section 85, including under co-payment medicines

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	13,211	7,834	3,577	1,598	3,338	1,060	76	886	31,580
FLUVASTATIN	44	11	6	-	-	-	-	-	61
LEVONORGESTREL	204	117	93	41	85	41	-	34	615
LEVONORGESTREL + ETHINYLESTRADIOL	2,752	1,725	1,151	504	800	548	18	269	7,767
NORETHISTERONE	155	97	48	19	29	12	-	18	378
NORETHISTERONE + ETHINYLESTRADIOL	103	63	35	18	16	24	-	12	271
PRAVASTATIN	911	374	171	84	185	45	-	66	1,836
ROSUVASTATIN	18,276	9,356	4,506	2,159	3,448	1,475	37	897	40,154
SIMVASTATIN	2,417	1,471	456	275	440	225	8	142	5,434
Total	38,073	21,048	10,043	4,698	8,341	3,430	139	2,324	88,096

Table 16(b): PBS/RPBS Continued Dispensing Medicines Government Cost by Dispensing Pharmacy State, 2021-22

Section 85, including under co-payment medicines

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	\$94,420	\$56,016	\$25,654	\$11,757	\$22,820	\$7,633	\$360	\$4,875	\$223,535
FLUVASTATIN	\$1,541	\$373	\$175	\$0	\$0	\$0	\$0	\$0	\$2,089
LEVONORGESTREL	\$1,157	\$537	\$342	\$801	\$145	\$170	\$0	\$3,399	\$6,550
LEVONORGESTREL + ETHINYLESTRADIOL	\$8,074	\$4,923	\$3,217	\$1,582	\$1,958	\$2,085	\$23	\$560	\$22,423
NORETHISTERONE	\$2,421	\$958	\$459	\$227	\$339	\$111	\$0	\$131	\$4,646
NORETHISTERONE + ETHINYLESTRADIOL	\$273	\$197	\$56	\$71	\$70	\$57	\$0	\$0	\$724
PRAVASTATIN	\$7,351	\$3,051	\$1,366	\$775	\$1,289	\$326	\$0	\$423	\$14,581
ROSUVASTATIN	\$123,327	\$62,413	\$30,009	\$14,573	\$21,930	\$10,223	\$162	\$4,415	\$267,051
SIMVASTATIN	\$18,676	\$11,181	\$3,157	\$2,154	\$3,337	\$1,511	\$73	\$850	\$40,940
Total	\$257,239	\$139,648	\$64,437	\$31,941	\$51,887	\$22,116	\$618	\$14,653	\$582,539

Note:

Includes medicines listed under National Health (Continued Dispensing) Determination 2012 legislation, dispensed under ongoing or emergency measures.

Excludes other medicines covered by Continued Dispensing Arrangements expansion (Emergency Measures) from January 2020. For more information, please see Table 16(c) and 16(d).

Small cells with counts less than 6 are suppressed and removed from the total.

Table 16(c): PBS/RPBS Medicines Supplied under Continued Dispensing (Emergency Measures) by ATC Level 1 and Dispensing Pharmacy State, 2021-22

Section 85, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	50,497	27,561	12,123	5,688	10,893	3,727	145	3,019	113,653
ANTIINFECTIVES FOR SYSTEMIC USE	3,340	1,539	889	322	722	232	-	204	7,248
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	2,823	1,563	621	288	629	234	-	272	6,430
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	32	12	6	-	-	-	-	-	50
BLOOD AND BLOOD FORMING ORGANS	12,901	6,742	3,427	1,516	2,798	846	36	802	29,068
CARDIOVASCULAR SYSTEM	129,504	70,523	32,953	15,583	27,244	10,561	449	7,268	294,085
DERMATOLOGICALS	1,775	1,007	320	173	435	157	-	117	3,984
GENITO URINARY SYSTEM AND SEX HORMONES	8,239	4,651	2,596	1,277	2,406	1,038	33	666	20,906
MUSCULO-SKELETAL SYSTEM	9,945	4,496	2,456	1,100	2,527	825	30	663	22,042
NERVOUS SYSTEM	56,162	30,762	18,141	7,182	14,348	5,615	202	4,148	136,560
RESPIRATORY SYSTEM	14,671	8,459	4,173	1,840	3,173	1,460	48	1,056	34,880
SENSORY ORGANS	7,435	3,532	1,756	629	1,546	444	19	328	15,689
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	5,772	2,927	1,498	707	1,528	556	19	384	13,391
VARIOUS	166	77	17	10	28	28	-	8	334
TOTAL	303,262	163,851	80,976	36,315	68,277	25,723	981	18,935	698,320

Table 16(d): PBS/RPBS Continued Dispensing Medicines (Emergency Measures) Government Cost by ATC Level 1 and Dispensing Pharmacy State, 2021-22

Section 85, including under co-payment medicines

ATC Group Level 1	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ALIMENTARY TRACT AND METABOLISM	\$1,399,770	\$821,265	\$349,026	\$157,600	\$304,394	\$101,454	\$3,496	\$87,766	\$3,224,771
ANTIINFECTIVES FOR SYSTEMIC USE	\$53,087	\$25,136	\$10,304	\$5,175	\$12,340	\$2,989	\$0	\$2,655	\$111,685
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$1,049,065	\$555,023	\$170,548	\$91,614	\$158,029	\$95,172	\$0	\$180,806	\$2,300,258
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$1,447	\$173	\$1,041	\$0	\$0	\$0	\$0	\$0	\$2,661
BLOOD AND BLOOD FORMING ORGANS	\$579,645	\$317,267	\$154,722	\$69,409	\$128,181	\$38,446	\$1,316	\$40,917	\$1,329,904
CARDIOVASCULAR SYSTEM	\$1,231,014	\$668,266	\$312,774	\$146,334	\$249,523	\$100,025	\$2,683	\$62,832	\$2,773,451
DERMATOLOGICALS	\$56,367	\$36,908	\$9,099	\$3,058	\$9,245	\$5,890	\$0	\$5,376	\$125,942
GENITO URINARY SYSTEM AND SEX HORMONES	\$96,113	\$51,107	\$25,637	\$12,607	\$26,375	\$8,266	\$136	\$9,661	\$229,902
MUSCULO-SKELETAL SYSTEM	\$169,106	\$78,334	\$34,008	\$15,938	\$38,326	\$9,869	\$135	\$26,743	\$372,459
NERVOUS SYSTEM	\$826,691	\$435,958	\$322,623	\$90,152	\$158,793	\$74,516	\$1,474	\$62,032	\$1,972,240
RESPIRATORY SYSTEM	\$492,049	\$278,897	\$129,034	\$51,361	\$99,228	\$43,902	\$1,040	\$32,209	\$1,127,720
SENSORY ORGANS	\$383,579	\$60,185	\$105,612	\$10,792	\$27,740	\$7,420	\$226	\$4,834	\$600,387
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$75,827	\$38,557	\$19,747	\$9,385	\$18,712	\$7,233	\$165	\$3,753	\$173,380
VARIOUS	\$45,868	\$16,802	\$4,023	\$2,393	\$4,615	\$3,100	\$0	\$1,204	\$78,004
TOTAL	\$6,459,627	\$3,383,877	\$1,648,199	\$665,817	\$1,235,501	\$498,283	\$10,671	\$520,788	\$14,422,763

Note:

Continued Dispensing Emergency Measures came into effect on 13 January 2020 and ended on 30 June 2022

Includes medicines listed under National Health (Continued Dispensing – Emergency Measures) Determination 2020, dispensed under ongoing or emergency measures.

Small cells with counts less than 6 are suppressed and removed from the total.

Table 17: Remuneration for Community Pharmacies and Friendly Societies¹ for PBS subsidised prescriptions, 2020-21 to 2021-22
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenditure for PBS and RPBS Prescriptions	2020-21	2021-22
Price to Pharmacists			
	Ex-Manufacturer Price	\$7,364,145,132	\$8,442,989,589
	Wholesale Mark-up	\$425,198,297	\$457,474,765
	Sub total	\$7,789,343,429	\$8,900,464,353
Administration, Handling and Storage Costs			
	AHI fee*	\$1,125,851,764	\$1,159,334,248
	Sub total	\$1,125,851,764	\$1,159,334,248
	*Administration, Handling and Infrastructure fee, formerly known as Pharmacy Mark-up		
Pharmacist's Specialised Skills in Dispensing the Medicines			
	Dispensing Fee	\$1,669,737,400	\$1,687,448,521
	Dangerous Drug Fee	\$40,651,128	\$41,274,610
	Wastage	\$4,299,596	\$6,338,935
	Container Fee	\$1,416,280	\$1,136,133
	Sub total	\$1,716,104,405	\$1,736,198,198
Other			
	Electronic Prescription Fee	\$14,878,250	\$19,332,888
	Sub total	\$14,878,250	\$19,332,888
	Total²	\$10,646,177,847	\$11,815,329,688

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	\$7,364,145,132	\$8,442,989,589
Wholesale cost	\$425,198,297	\$457,474,765
Pharmacy cost	\$2,856,834,419	\$2,914,865,335
Total	\$10,646,177,847	\$11,815,329,688

This table was amended on 2 August 2023 to correct a transposition error in the 2020-21 and 2021-22 data columns.

1. Table 17 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

* Includes Efficient Funding of Chemotherapy (EFC) items dispensed by community pharmacies and friendly societies from March 2021 (EFC excluded prior to this as the pricing components were not available in the PBS online claims data).

* Includes private and public hospital HSD claims dispensed by community pharmacies and friendly societies.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

2. Health's 2021-22 Annual Report lists the administered expenses for pharmaceutical benefits as \$14.7 billion. The difference between that figure and the total figure above is attributable to:

* the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and some s100 data for community pharmacy and friendly societies only (it excludes a number of smaller s100 programs, for example the Opiate Dependence Treatment Program and Remote Area Aboriginal Health Services Program).

* the annual report data is based on accrual figures, whilst the above data is cash basis;

* the annual report does not include patient contributions;

* the annual report data does not include the Electronic Prescription Fee;

* the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS, and

* the annual report also excludes the items in the footnote 1 above.

Table 18: CPA Professional Pharmacy Programs Expenditure, 2021-22

Under the Seventh CPA there were a range of professional programs and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programs under the 7CPA in 2021-22 by relevant categories.

Program Type	Actual Expenditure
Rural Pharmacy Maintenance Allowance	\$21,000,000
Rural Pharmacy Workforce Program	\$4,875,000
Medication Management services	\$83,250,000
Medication Adherence services	\$121,700,000
Aboriginal & Torres Strait Islander programs	\$3,940,000
Pharmacy Program administration fees	\$8,097,464
Programs Total	\$242,862,464

Notes:

1. For the Programs administration arrangements for 2021-22 the total funding provided to the Pharmacy Programs Administrator (i.e Australian Healthcare Associates) was \$242,862,464. Of this, \$8,097,464.35 (GST excl) was provided to the Pharmacy Programs Administrator for the purpose of Pharmacy Program administration fees. This means the Pharmacy Programs Administrator administration fees was 3.33% of the total funds.

2. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 17 of the report.

3. Rural Pharmacy Workforce Program, Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

Rural Pharmacy Workforce Program consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$80,000
Emergency Locum Service	\$200,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$675,000
Undergraduate Pharmacy-Scholarship Scheme	\$1,200,000
CPE - Continuing Professional Education Allowance	\$300,000
Pharmacy - Rural Administration Support	\$470,000
Rural Pharmacy - Mentor Scheme	\$50,000
Post Intern Incentive Allowance	\$260,000
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$800,000
RPLO	\$840,000
Program Total	\$4,875,000

Medication Management services consist of the following elements:	Actual Expenditure
Diabetes Medscheck and Medscheck	\$40,000,000
Residential Medication Management Review (RMMR)	\$13,250,000
Home Medicines Review (HMR)	\$22,000,000
Quality Use of Medicines (QUM)	\$8,000,000
Program Total	\$83,250,000

Medication Adherence services consist of the following elements:	Actual Expenditure
Dose Administration Aids	\$98,000,000
Indigenous Dose Administration Aids	\$15,000,000
Staged Supply	\$8,700,000
Program Total	\$121,700,000

Aboriginal & Torres Strait Islander Programs consist of the following elements:	Actual Expenditure
Workforce (scholarships)	\$180,000
Workforce (traineeships)	\$160,000
Indigenous Health Services Pharmacy Support Program (IHSPS)	\$3,600,000
Program Total	\$3,940,000

Table 19: Actual Costs of Major Components of CPA*, 2021-22

Component	Expenditure
Pharmacy remuneration	\$2,914,865,335
Wholesale remuneration	\$457,474,765
Professional programs	\$242,862,464
Community Services Obligation (CSO)	\$215,000,000
Total	\$3,830,202,563

* The current Community Pharmacy Agreement is the 7th CPA.

Notes:

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programs and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Department of Health and Aged Care receives from Services Australia. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

Table 20: Community Services Obligation (CSO) Expenditure, 2021-22

Component	Expenditure
CSO funding pool	\$213,608,943
CSO admin	\$1,391,057
Total	\$215,000,000

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health and Aged Care.

PBS INFORMATION LINE REPORT, 2021-22

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1st July 2021 – 30th June 2022, the information line answered 5,382 calls. This was a decrease of 13.4% from the previous financial year, where 6,105 calls were answered.

Breakdown of calls by month:

Month	Number of calls
July 2021	468
August 2021	446
September 2021	461
October 2021	534
November 2021	439
December 2021	332
January 2022	342
February 2022	400
March 2022	472
April 2022	407
May 2022	522
June 2022	559
Total	5,382

National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2021 until 30 June 2024.

The NDSS is managed by the Department of Health and Aged Care through the Diabetes Support and CSO Section, in the Pharmacy Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin pump consumables products, continuous glucose monitoring products, and blood and urine testing strips, and are available through NDSS Access Points nationally. Access Points mainly comprise community pharmacies plus a very small number of other entities, such as health centres, hospitals and aged care facilities. There are currently over 5,600 NDSS Access Points operating in Australia.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%
2017-18	403,307	1.7%	873,632	1.6%	1,276,939	1.7%
2018-19	416,269	3.2%	892,801	2.2%	1,309,070	2.52%
2019-20	438,365	5.3%	928,492	4%	1,366,857	4.4%
2020-21	443,572	1.19%	945,903	1.88%	1,389,475	1.65%
2021-22	466,014	5.1%	988,155	4.45%	1,454,169	4.7%

National Diabetes Services Scheme Expenditure

Total NDSS expenditure for products for the 2021-22 financial year was \$196m. From 2016-17, NDSS Registrant co-payments for subsidised products, are now returned to Consolidated Revenue.

Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2021-22)

PRESCRIPTIONS	GENERAL	PENSIONER	CONC	S/NET	TOTAL	DRS BAG	TOTAL - ALL PRESCRIPTIONS
1948-49	280,719				280,719		280,719
1949-50	484,210				484,210		484,210
1950-51	3,758,622				3,758,622		3,758,622
1951-52	6,515,668	1,655,570			8,171,238		8,171,238
1952-53	6,853,937	2,766,947			9,620,884		9,620,884
1953-54	7,004,421	3,453,551			10,457,972		10,457,972
1954-55	9,201,387	4,418,633			13,620,020		13,620,020
1955-56	8,970,890	5,235,013			14,205,903		14,205,903
1956-57	9,045,439	5,580,946			14,626,385		14,626,385
1957-58	10,309,446	6,313,214			16,622,660		16,622,660
1958-59	13,253,168	6,821,578			20,074,746		20,074,746
1959-60	16,624,342	8,028,968			24,653,310		24,653,310
1960-61	20,489,065	10,727,570			31,216,635		31,216,635
1961-62	26,050,370	11,664,036			37,714,406		37,714,406
1962-63	29,517,810	12,674,230			42,192,040		42,192,040
1963-64	31,039,624	13,317,273			44,356,897		44,356,897
1964-65	33,714,429	13,841,372			47,555,801		47,555,801
1965-66	35,084,551	14,908,393			49,992,944		49,992,944
1966-67	36,750,907	16,936,435			53,687,342		53,687,342
1967-68	37,053,212	18,369,634			55,422,846		55,422,846
1968-69	40,453,366	19,954,471			60,407,837		60,407,837
1969-70	44,071,198	21,504,166			65,575,364		65,575,364
1970-71	48,971,406	22,515,117			71,486,523		71,486,523
1971-72	48,491,692	23,950,503			72,442,195		72,442,195
1972-73	49,115,497	25,560,576			74,676,073		74,676,073
1973-74	59,499,823	27,788,036			87,287,859		87,287,859
1974-75	67,350,637	30,323,662			97,674,299		97,674,299
1975-76	67,722,534	33,394,757			101,117,291		101,117,291
1976-77	56,099,277	33,606,128			89,705,405		89,705,405
1977-78	57,751,904	35,414,619			93,166,523		93,166,523
1978-79	53,553,036	39,409,489			92,962,525		92,962,525
1979-80	46,624,224	42,450,386			89,074,610		89,074,610
1980-81	47,619,120	46,778,057			94,397,177		94,397,177
1981-82	53,834,648	49,739,756			103,574,404		103,574,404
1982-83	50,078,929	52,529,929	2,931,462		105,540,320		105,540,320
1983-84	41,938,964	56,491,285	9,954,995		108,385,244		108,385,244
1984-85	50,690,275	60,069,806	10,068,817		120,828,898		120,828,898
1985-86	46,334,279	63,191,858	10,315,799		119,841,936		119,841,936
1986-87	28,762,909	64,243,148	9,755,680	2	102,761,737		102,761,737
1987-88	12,339,360	81,041,242	7,520,752	15,059,811	100,901,354		100,901,354
1988-89	14,078,934	78,283,599	8,223,231	11,925,271	100,585,764		100,585,764
1989-90	15,361,517	80,761,310	8,856,241	11,725,474	104,979,068		104,979,068
1990-91	10,608,974	36,868,817	36,588,405	11,675,164	95,741,360	558,899	96,300,259

Notes

- Dr's Bag prior to 1990-91 included in General, from 1990-91 included in miscellaneous expenditure
- For 1990-91 Concessional includes 'old' (prior to 1/11/90) prescriptions and 'new' (post 1/11/90) concessional category
- Exclude under co-payment prescriptions

Safety Net
Prior to 1990-91 S/net for Gen & Concess is included in pensioner. In 1990-91 free s/net is in both pensioner and s/net categories

PBS Expenditure and Prescriptions 2021-22

Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2021-22) Continued

PRESCRIPTIONS	GENERAL				CONCESSIONAL			TOTAL PRESCRIPTIONS	DRS BAG	TOTAL- ALL PRESCRIPTIONS
	NSN	S/Net 1	S/NET 2	TOTAL	NSN	S/NET	TOTAL			
1991-92	8,266,835	2,340,145	1,092,314	11,699,294	67,331,793	14,428,608	81,760,401	93,459,695	660,459	94,120,154
1992-93	10,260,426	3,917,022	2,800,496	16,977,944	71,756,325	16,757,840	88,514,165	105,492,109	689,508	106,181,617
1993-94	11,451,148	4,259,245	3,087,943	18,798,336	77,536,126	18,003,354	95,539,480	114,337,816	704,227	115,042,043
1994-95	13,491,364	4,695,314	2,072	18,188,750	82,400,588	17,457,008	99,857,596	118,046,346	674,331	118,720,677
1995-96	14,212,731	5,488,957	52	19,701,740	85,604,215	18,898,907	104,503,122	124,204,862	683,420	124,888,282
1996-97	14,709,601	3,082,843	14	17,792,458	85,965,797	19,676,007	105,641,804	123,434,262	665,301	124,099,563
1997-98	14,087,393	3,945,591	17	18,033,001	86,389,807	20,060,505	106,450,312	124,483,313	628,496	125,111,809
1998-99	15,153,975	4,111,091		19,265,066	88,475,327	20,608,073	109,083,400	128,348,466	572,753	128,921,219
1999-00	16,296,703	3,928,760		20,225,463	94,281,872	23,078,282	117,360,154	137,585,617	496,306	138,081,923
2000-01	18,526,141	4,340,364		22,866,505	99,285,160	25,420,114	124,705,274	147,571,779	478,999	148,050,778
2001-02	19,292,104	4,813,038		24,105,142	102,018,211	28,406,603	130,424,814	154,529,956	448,283	154,978,239
2002-03	20,694,131	5,188,492		25,882,623	101,459,056	31,177,491	132,636,547	158,519,170	437,516	158,956,686
2003-04	22,443,338	5,544,618		27,987,956	104,619,866	32,827,303	137,447,169	165,435,125	426,976	165,862,101
2004-05	22,194,451	6,209,302		28,403,753	105,377,946	36,095,311	141,473,257	169,877,010	402,492	170,279,502
2005-06	20,917,523	5,910,828		26,828,351	105,152,486	35,945,690	141,098,176	167,926,527	396,088	168,322,615
2006-07	19,871,669	4,710,422		24,582,091	110,917,202	32,675,864	143,593,066	168,175,157	360,362	168,535,519
2007-08	19,607,454	4,553,340		24,160,794	113,118,234	33,680,813	146,799,047	170,959,841	336,182	171,296,023
2008-09	20,746,777	5,580,636		26,327,413	119,906,347	35,234,371	155,140,718	181,468,131	367,996	181,836,127
2009-10	21,226,750	4,763,435		25,990,185	122,832,364	34,756,644	157,589,008	183,579,193	332,344	183,911,537
2010-11	21,032,398	4,943,233		25,975,631	125,446,923	36,381,986	161,828,909	187,804,540	337,715	188,142,255
2011-12	21,239,413	4,820,643		26,060,056	130,441,952	38,046,697	168,488,649	194,548,705	324,424	194,873,129
2012-13	19,323,589	4,371,046		23,694,635	133,646,630	39,611,994	173,258,624	196,953,259	352,123	197,305,382
2013-14	18,050,307	4,052,529		22,102,836	145,340,393	42,009,011	187,349,404	209,452,240	363,763	209,816,003
2014-15	15,902,515	3,544,902		19,447,417	147,979,717	44,277,679	192,257,396	211,704,813	380,376	212,085,189
2015-16	13,770,978	3,180,897		16,951,875	146,529,394	44,119,861	190,649,255	207,601,130	388,859	207,989,989

New Series	GENERAL			CONCESSIONAL			TOTAL PBS	DRS BAG	MISC and S100	TOTAL - ALL PRESCRIPTIONS
	NSN	S/Net	TOTAL	NSN	S/Net	TOTAL				
2016-17	12,334,542	2,699,345	15,033,887	144,336,986	36,045,418	180,382,404	195,416,291	394,352	2,560,813	198,371,456
2017-18	13,332,423	2,616,813	15,949,236	148,018,925	37,047,645	185,066,570	201,015,806	398,051	2,645,790	204,059,647
2018-19	13,490,749	2,637,491	16,128,240	148,244,490	37,499,894	185,744,384	201,872,624	402,827	2,813,028	205,088,479
2019-20	13,873,735	2,577,950	16,451,685	148,326,789	40,280,313	188,607,102	205,058,787	418,823	2,992,062	208,469,672
2020-21	13,965,778	2,787,346	16,753,124	142,641,141	50,569,557	193,210,698	209,963,822	360,456	3,243,777	213,568,055
2021-22	15,874,460	2,847,994	18,722,454	142,223,258	50,372,858	192,596,116	211,318,570	355,487	3,343,661	215,017,718

CONC: Concessional

S/NET: Safety Net

PENSIONER: Before 1 November 1990 pensioners received PBS drugs free of charge.

NSN: Non Safety Net

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

MISC and SECT 100: Section 100 programs.

Note: From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, prescriptions were reported by the date that they were processed by Services Australia.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2021-22)

YEAR	GOVERNMENT EXPENDITURE \$-					SUB TOTAL	HOSP & MISC		TOTAL GOVT COST		PATIENT CONTRIBUTION			TOTAL COST PRESCRIPTIONS	TOTAL with S.100 & Misc
	GEN	CONC	PENS	SAFETY NET			MISC		GEN	CON	TOTAL				
1948-49	132,536				132,536	165,538		298,074						132,536	298,074
1949-50	346,682				346,682	262,696		609,378						346,682	609,378
1950-51	5,453,558				5,453,558	406,768		5,860,326						5,453,558	5,860,326
1951-52	13,424,294		715,264		14,139,558	1,230,536		15,370,094						14,139,558	15,370,094
1952-53	12,399,568		1,457,316		13,856,884	573,734		14,430,618						13,856,884	14,430,618
1953-54	14,320,372		2,021,560		16,341,932	2,116,894		18,458,826						16,341,932	18,458,826
1954-55	16,303,940		2,589,672		18,893,612	2,585,322		21,478,934						18,893,612	21,478,934
1955-56	18,061,092		3,015,920		21,077,012	2,697,858		23,774,870						21,077,012	23,774,870
1956-57	17,171,670		3,586,200		20,757,870	2,675,776		23,433,646						20,757,870	23,433,646
1957-58	22,826,484		4,246,490		27,072,974	2,995,004		30,067,978						27,072,974	30,067,978
1958-59	33,112,570		5,034,746		38,147,316	3,798,278		41,945,594						38,147,316	41,945,594
1959-60	36,714,806		7,148,446		43,863,252	4,808,090		48,671,342	1,890,756		1,890,756			45,754,008	50,562,098
1960-61	34,282,496		14,676,698		48,959,194	6,803,248		55,762,442	10,324,740		10,324,740			59,283,934	66,087,182
1961-62	44,632,488		18,194,996		62,827,484	7,552,282		70,379,766	13,007,776		13,007,776			75,835,260	83,387,542
1962-63	47,093,026		19,830,750		66,923,776	9,986,382		76,910,158	14,742,448		14,742,448			81,666,224	91,652,606
1963-64	46,460,998		20,601,714		67,062,712	11,775,958		78,838,670	15,573,804		15,573,804			82,636,516	94,412,474
1964-65	48,929,748		21,564,420		70,494,168	11,708,442		82,202,610	16,841,354		16,841,354			87,335,522	99,043,964
1965-66	53,078,046		24,071,127		77,149,173	14,634,501		91,783,674	17,481,228		17,481,228			94,630,401	109,264,902
1966-67	56,655,939		29,280,268		85,936,207	15,344,592		101,280,799	18,347,036		18,347,036			104,283,243	119,627,835
1967-68	56,800,249		32,115,335		88,915,584	16,218,859		105,134,443	18,504,345		18,504,345			107,419,929	123,638,788
1968-69	64,024,983		36,609,257		100,634,240	17,739,118		118,373,358	20,129,402		20,129,402			120,763,642	138,502,760
1969-70	73,227,887		41,068,702		114,296,589	22,421,727		136,718,316	21,941,691		21,941,691			136,238,280	158,660,007
1970-71	88,176,385		45,180,856		133,357,241	26,917,666		160,274,907	24,384,028		24,384,028			157,741,269	184,658,935
1971-72	90,061,869		52,005,350		142,067,219	31,201,229		173,268,448	35,466,642		35,466,642			177,533,861	208,735,090
1972-73	87,431,438		58,139,459		145,570,897	32,061,691		177,632,588	48,640,243		48,640,243			194,211,140	226,272,831
1973-74	108,066,351		66,802,821		174,869,172	43,426,672		218,295,844	59,015,335		59,015,335			233,884,507	277,311,179
1974-75	131,341,320		80,586,986		211,928,306	50,368,781		262,297,087	66,827,982		66,827,982			278,756,288	329,125,069
1975-76	149,033,245		107,317,318		256,350,563	27,490,706		283,841,269	95,244,660		95,244,660			351,595,223	379,085,929
1976-77	111,077,507		115,201,775		226,279,282	8,623,582		234,902,864	111,676,421		111,676,421			337,955,703	346,579,285
1977-78	118,303,375		127,911,837		246,215,212	9,832,410		256,047,622	115,025,169		115,025,169			361,240,381	371,072,791
1978-79	110,425,438		151,125,681		261,551,119	9,767,502		271,318,621	129,540,759		129,540,759			391,091,878	400,859,380
1979-80	101,185,503		166,361,113		267,546,616	7,088,452		274,635,068	123,418,168		123,418,168			390,964,784	398,053,236
1980-81	107,903,558		191,043,798		298,947,356	10,267,063		309,214,419	129,923,272		129,923,272			428,870,628	439,137,691
1981-82	139,547,856		239,894,493		379,442,349	11,377,241		390,819,590	157,957,635		157,957,635			537,399,984	548,777,225
1982-83	131,773,044	11,100,973	272,707,495		415,581,512	14,685,428		430,266,940	170,617,530	5,882,844	176,500,374			592,081,886	606,767,314
1983-84	114,638,367	39,276,732	317,819,660		471,734,759	17,490,165		489,224,924	166,043,447	19,975,026	186,018,473			657,753,232	675,243,397
1984-85	142,439,672	43,266,712	356,213,948		541,920,332	17,877,162		559,797,494	201,142,242	20,208,116	221,350,358			763,270,690	781,147,852
1985-86	138,365,148	50,172,930	408,026,507		596,564,585	19,258,116		615,822,701	222,286,396	20,715,057	243,001,453			839,566,038	858,824,154
1986-87	140,571,611	59,738,152	514,236,037		714,545,800	23,457,302		738,003,102	167,130,307	22,048,299	189,178,607			903,724,406	927,181,708
1987-88	111,740,361	51,574,897	747,536,316	12	910,851,574	35,612,019		946,463,593	117,938,301	18,839,286	136,777,587			1,047,629,161	1,083,241,180
1988-89	132,040,607	63,272,252	795,027,196	138,531,290	990,340,055	33,194,842		1,023,534,897	147,704,171	20,603,194	168,307,365			1,158,647,420	1,191,842,262
1989-90	170,039,203	74,757,555	890,753,297	150,064,548	1,135,550,055	43,852,385		1,179,402,440	162,587,554	22,174,539	184,762,093			1,320,312,148	1,364,164,533
1990-91	157,783,001	342,720,328	428,743,821	580,709,870	1,094,463,443	64,798,247		1,159,261,690	132,120,868	91,672,986	223,793,854			1,318,257,297	1,383,055,544

Note
 -Free Pensioner category removed from 1 Nov 1990, \$2.50 copayment and free safety net introduced for all Concessionals
 -Dr's Bag prior to 1990-91 included in General from 1990-91 (\$12,255,895) included in Misc

Safety Net

-For Gen & Conc prior to 1990-91 is included in Pensioner
 -For 1990-91 S/net includes both pre & post 1/11/90 free Snet
 -Gen S/net 1 included in Concess in 1990-91
 -Gen S/net 2 (free) 1 Jan 1991 to 31 Dec 1993

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2021-22) Continued

GOVERNMENT EXPENDITURE - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
1991-92	160,765,548	36,400,482	18,911,584	216,077,614	708,413,833	195,000,082	903,413,915	1,119,491,529	100,877,826	1,220,369,355	
1992-93	188,270,160	65,845,466	53,077,875	307,193,500	844,972,301	251,249,539	1,096,221,840	1,403,415,340	101,552,426	1,504,967,766	
1993-94	224,675,364	78,832,510	63,861,452	367,369,326	1,019,651,580	297,597,894	1,317,249,474	1,684,618,800	116,696,888	1,801,315,688	
1994-95	290,765,883	93,406,668	38,565	384,211,116	1,194,999,580	302,502,892	1,497,502,472	1,881,713,588	109,621,215	1,991,334,803	
1995-96	343,025,066	118,655,085	785	461,680,936	1,369,432,585	360,130,508	1,729,563,093	2,191,244,029	135,473,133	2,326,717,162	
1996-97	392,246,135	72,831,781	210	465,078,126	1,465,657,637	401,814,359	1,867,471,996	2,332,550,122	205,545,012	2,538,095,134	
1997-98	411,856,192	98,613,376	465	510,470,033	1,576,058,096	439,989,321	2,016,047,417	2,526,517,450	258,950,240	2,785,467,690	
1998-99	469,042,094	106,618,491	-	575,660,585	1,739,535,268	467,079,112	2,206,614,380	2,782,274,965	287,469,135	3,069,744,100	
1999-00	521,018,128	107,012,848	-	628,030,976	2,000,636,597	547,829,734	2,548,466,331	3,176,497,307	311,727,262	3,488,224,569	
2000-01	662,099,200	128,173,886	-	790,273,086	2,359,650,038	660,303,947	3,019,953,985	3,810,227,071	347,901,802	4,158,128,873	
2001-02	691,204,687	148,498,520	-	839,703,207	2,569,555,585	778,411,796	3,347,967,381	4,187,670,588	396,386,682	4,584,057,270	
PATIENT CONTRIBUTION - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
1991-92	128,988,053	6,043,066	-	135,031,119	173,201,117	-	173,201,117	308,232,236	1,427,723,765	100,877,826	1,528,601,591
1992-93	162,967,769	10,202,578	-	173,170,347	186,726,902	-	186,726,902	359,897,249	1,763,312,589	101,552,426	1,864,865,015
1993-94	183,012,475	11,074,025	-	194,086,500	201,596,301	-	201,596,301	395,682,801	2,080,301,601	116,696,888	2,196,998,489
1994-95	218,094,751	12,207,816	-	230,302,567	214,241,512	-	214,241,512	444,544,079	2,326,257,667	109,621,215	2,435,878,882
1995-96	237,239,817	14,278,699	-	251,518,516	226,583,554	-	226,583,554	478,102,070	2,669,346,099	135,473,133	2,804,819,232
1996-97	269,715,066	8,375,980	-	278,091,046	252,104,590	-	252,104,590	530,195,636	2,862,745,758	205,545,012	3,068,290,770
1997-98	281,739,252	12,625,016	-	294,364,268	276,440,026	-	276,440,026	570,804,294	3,097,321,744	258,950,240	3,356,271,984
1998-99	305,064,052	13,155,417	-	318,219,469	283,117,963	-	283,117,963	601,337,432	3,383,612,397	287,469,135	3,671,081,532
1999-00	333,003,549	12,584,337	-	345,587,886	306,183,001	-	306,183,001	651,770,887	3,828,268,194	311,727,262	4,139,995,456
2000-01	392,432,536	14,353,837	-	406,786,373	337,379,028	-	337,379,028	744,165,401	4,554,392,472	347,901,802	4,902,294,274
2001-02	426,974,621	16,864,336	-	443,838,957	362,237,529	-	362,237,529	806,076,486	4,993,747,074	396,386,682	5,390,133,756
DOCTOR'S BAG - \$ - (included in miscellaneous from 1990-91)											
1990-91		12,255,895									
1991-92		14,514,725									
1992-93		16,082,655									
1993-94		16,679,933									
1994-95		15,674,643									
1995-96		16,202,098									
1996-97		15,769,173									
1997-98		14,953,823									
1998-99		13,370,491									
1999-00		10,754,395									
2000-01		10,343,534									
2001-02		9,803,682									

note- from 1991-92 all figures are sourced from the Services Australia processing where available
 -miscellaneous and section 100 expenditure sourced from Department of Health and Aged Care and Services Australia payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2021-22) Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2002-03	\$747,049,026	\$169,693,390	\$916,742,416	\$2,741,874,040	\$907,119,434	\$3,648,993,474	\$4,565,735,890	\$477,352,298	\$5,043,088,188	
2003-04	\$824,130,608	\$190,682,979	\$1,014,813,587	\$2,972,331,634	\$1,004,522,779	\$3,976,854,413	\$4,991,668,000	\$570,500,000	\$5,562,168,000	
2004-05	\$850,690,906	\$222,668,220	\$1,073,359,125	\$3,077,033,801	\$1,145,497,231	\$4,222,531,032	\$5,295,890,157	\$668,500,000	\$5,964,390,157	
2005-06	\$850,095,680	\$216,246,563	\$1,066,342,242	\$3,145,480,431	\$1,172,502,111	\$4,317,982,542	\$5,384,324,784	\$764,000,000	\$6,148,324,784	
2006-07	\$890,275,536	\$174,127,771	\$1,064,403,307	\$3,333,875,949	\$1,067,478,074	\$4,401,354,023	\$5,465,757,330	\$886,500,000	\$6,352,257,330	
2007-08	\$1,039,451,749	\$173,499,550	\$1,212,951,299	\$3,561,294,283	\$1,137,925,393	\$4,699,219,676	\$5,912,170,974	\$975,500,000	\$6,887,670,974	
2008-09	\$1,220,279,806	\$217,487,483	\$1,437,767,290	\$3,909,584,010	\$1,216,050,241	\$5,125,634,250	\$6,563,401,540	\$1,081,400,000	\$7,644,801,540	
2009-10	\$1,339,182,210	\$199,599,002	\$1,538,781,212	\$4,220,391,341	\$1,259,719,602	\$5,480,110,943	\$7,018,892,155	\$1,232,400,000	\$8,251,292,155	
2010-11	\$1,412,781,352	\$211,944,918	\$1,624,726,270	\$4,367,739,898	\$1,330,682,636	\$5,698,422,533	\$7,323,148,803	\$1,335,500,000	\$8,658,648,803	
2011-12	\$1,453,773,280	\$208,167,009	\$1,661,940,288	\$4,476,104,435	\$1,390,159,396	\$5,866,263,831	\$7,528,204,119	\$1,473,700,000	\$9,001,904,119	
2012-13	\$1,339,654,102	\$169,213,844	\$1,508,867,945	\$4,209,086,581	\$1,351,536,398	\$5,560,622,979	\$7,069,490,924	\$1,812,600,000	\$8,882,090,924	
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2002-03	\$470,306,937	\$18,698,099	\$489,005,036	\$370,426,183	-	\$370,426,183	\$859,431,219	\$5,425,167,109	\$477,352,298	\$5,902,519,407
2003-04	\$524,763,848	\$20,538,514	\$545,302,362	\$392,513,143	-	\$392,513,143	\$937,815,505	\$5,929,483,505	\$570,500,000	\$6,499,983,505
2004-05	\$572,963,103	\$23,742,733	\$596,705,836	\$443,930,641	-	\$443,930,641	\$1,040,636,477	\$6,336,526,634	\$668,500,000	\$7,005,026,634
2005-06	\$606,897,345	\$27,199,070	\$634,096,415	\$489,173,277	-	\$489,173,277	\$1,123,269,692	\$6,507,594,476	\$764,000,000	\$7,271,594,476
2006-07	\$596,483,266	\$22,154,622	\$618,637,888	\$532,682,972	-	\$532,682,972	\$1,151,320,859	\$6,617,078,189	\$886,500,000	\$7,503,578,189
2007-08	\$607,183,393	\$22,323,024	\$629,506,417	\$559,962,883	-	\$559,962,883	\$1,189,469,300	\$7,101,640,274	\$975,500,000	\$8,077,140,274
2008-09	\$663,449,571	\$27,928,829	\$691,378,400	\$617,378,323	-	\$617,378,323	\$1,308,756,723	\$7,872,158,263	\$1,081,400,000	\$8,953,558,263
2009-10	\$701,961,714	\$25,253,391	\$727,215,106	\$656,949,638	-	\$656,949,638	\$1,384,164,743	\$8,403,056,898	\$1,232,400,000	\$9,635,456,898
2010-11	\$707,968,006	\$26,706,262	\$734,674,267	\$689,108,592	-	\$689,108,592	\$1,423,782,860	\$8,746,931,663	\$1,335,500,000	\$10,082,431,663
2011-12	\$735,994,339	\$27,003,502	\$762,997,841	\$742,139,779	-	\$742,139,779	\$1,505,137,620	\$9,033,341,739	\$1,473,700,000	\$10,507,041,739
2012-13	\$689,036,554	\$25,352,649	\$714,389,203	\$781,002,893	-	\$781,002,893	\$1,495,392,096	\$8,564,883,021	\$1,812,600,000	\$10,377,483,021
Doctor's Bag - \$ - (included in miscellaneous from 1990-91)										
2002-03	\$9,510,606									
2003-04	\$9,408,669									
2004-05	\$9,365,803									
2005-06	\$10,063,803									
2006-07	\$10,698,205									
2007-08	\$13,468,779									
2008-09	\$14,533,302									
2009-10	\$13,571,776									
2010-11	\$14,228,520									
2011-12	\$12,974,506									
2012-13	\$14,755,085									

note- from 1991-92 all figures are sourced from the Services Australia processing where available
 -miscellaneous and section 100 expenditure sourced from Department of Health and Aged Care and Services Australia payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional
 S/Net: Safety Net
 GEN: General
 NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.
 HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.
 PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Pharmaceutical Benefits Scheme History - Government Expenditure & Patient Contribution, 1948-49 to 2021-22 Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2013-14	\$1,429,860,300	\$154,692,449	\$1,584,552,749	\$4,319,414,670	\$1,388,583,542	\$5,707,998,212	\$7,292,550,961	\$2,033,900,000	\$9,326,450,961	
2014-15	\$1,463,256,600	\$129,523,975	\$1,592,780,575	\$4,123,482,128	\$1,380,416,342	\$5,503,898,470	\$7,096,679,044	\$2,183,101,118	\$9,279,780,162	
2015-16	\$1,785,357,915	\$118,821,879	\$1,904,179,793	\$4,630,980,302	\$1,413,858,158	\$6,044,838,460	\$7,949,018,254	\$2,752,825,107	\$10,701,843,361	
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	DRS BAG	MISC and S100	TOTAL GOVT EXP
2016-17	\$2,088,188,915	\$103,984,977	\$2,192,173,892	\$5,315,606,905	\$1,204,716,252	\$6,520,323,157	\$8,712,497,049	\$16,718,674	\$3,043,936,194	\$11,773,151,917
2017-18	\$1,981,594,072	\$101,429,150	\$2,083,023,223	\$5,127,198,161	\$1,236,961,876	\$6,364,160,037	\$8,447,183,260	\$16,568,617	\$3,139,112,049	\$11,602,863,926
2018-19	\$2,005,253,340	\$102,355,665	\$2,107,609,004	\$4,844,366,564	\$1,243,669,704	\$6,088,036,267	\$8,195,645,272	\$16,002,440	\$3,487,069,944	\$11,698,717,656
2019-20	\$2,142,135,695	\$104,447,648	\$2,246,583,343	\$4,918,980,015	\$1,370,238,848	\$6,289,218,863	\$8,535,802,207	\$16,858,042	\$3,954,440,736	\$12,507,100,984
2020-21	\$2,247,741,985	\$119,462,970	\$2,367,204,956	\$4,966,909,221	\$1,787,793,797	\$6,754,703,018	\$9,121,907,974	\$14,971,053	\$4,436,561,169	\$13,573,440,196
2021-22	\$2,707,518,000	\$128,887,707	\$2,836,405,707	\$5,179,039,991	\$1,843,118,166	\$7,022,158,157	\$9,858,563,864	\$14,228,777	\$4,577,775,056	\$14,450,567,697
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2013-14	\$656,913,329	\$23,915,012	\$680,828,341	\$864,226,399	-	\$864,226,399	\$1,545,054,740	\$8,837,605,701	\$2,033,900,000	\$10,871,505,701
2014-15	\$567,399,905	\$21,021,090	\$588,420,995	\$877,483,279	-	\$877,483,279	\$1,465,904,274	\$8,562,583,318	\$2,183,101,118	\$10,745,684,436
2015-16	\$494,124,051	\$19,115,443	\$513,239,494	\$880,965,644	-	\$880,965,644	\$1,394,205,138	\$9,343,223,391	\$2,752,825,107	\$12,096,048,498
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	TOTAL COST *	MISC and S100	TOTAL EXP **
2016-17	\$444,029,285	\$16,448,625	\$460,477,909	\$880,418,081	-	\$880,418,081	\$1,340,895,990	\$10,053,393,039	\$38,361,124	\$13,152,409,031
2017-18	\$484,120,874	\$16,143,997	\$500,264,871	\$915,055,636	-	\$915,055,636	\$1,415,320,507	\$9,862,503,767	\$40,183,135	\$13,058,367,568
2018-19	\$494,513,005	\$16,477,196	\$510,990,200	\$929,032,414	-	\$929,032,414	\$1,440,022,615	\$9,635,667,887	\$44,642,304	\$13,183,382,575
2019-20	\$512,660,643	\$16,287,445	\$528,948,088	\$942,085,948	-	\$942,085,948	\$1,471,034,036	\$10,006,836,242	\$48,802,754	\$14,026,937,774
2020-21	\$521,358,291	\$17,799,421	\$539,157,712	\$911,124,052	-	\$911,124,052	\$1,450,281,764	\$10,572,189,738	\$53,945,606	\$15,077,667,566
2021-22	\$595,270,318	\$18,163,632	\$613,433,949	\$920,942,920	-	\$920,942,920	\$1,534,376,869	\$10,656,284,843	\$58,203,759	\$15,166,020,824
TOTAL COST *	Total cost for Section 85 (Patient payment + Government benefit)									
TOTAL EXP **	Total PBS Expenditure, Section 85, Section 100 and Drs Bag (Patient payment + Government benefit)									
Doctor's Bag - \$ - (included in miscellaneous from 1990-91)										
2013-14	\$16,009,408									
2014-15	\$16,340,036									
2015-16	\$15,887,150									
2016-17	\$16,718,674									
2017-18	\$16,568,617									
2018-19	\$16,002,440									
2019-20	\$16,858,042									
2020-21	\$14,971,053									
2021-22	\$14,228,777									

Notes:

From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, Government expenditure and patient contributions were reported by the date that the prescriptions were processed by Services Australia.

From 1991-92 all figures are sourced from Services Australia processing where available

Miscellaneous and section 100 expenditure sourced from Department of Health and Aged Care and Services Australia payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Section 100 programs, other ungrouped expenditure

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.